

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
WO 03/092600 A2

- (51) International Patent Classification<sup>7</sup>: A61K
- (21) International Application Number: PCT/US03/13492
- (22) International Filing Date: 29 April 2003 (29.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/136,860 30 April 2002 (30.04.2002) US
- (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PORTNOY, Daniel A. [US/US]; 1196 Curtis Street, Albany, CA 94706 (US). CALENDAR, Richard [US/US]; 940 Euclid Avenue, Berkeley, CA 94708 (US). LAUER, Peter M. [US/US]; 5719 Oak Grove Avenue, Oakland, CA 94618 (US).
- (74) Agent: FIELD, Bret E.; Bozicevic, Field & Francis, 200 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SITE SPECIFIC LISTERIA INTEGRATION VECTORS AND METHODS FOR USING THE SAME



(57) Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.

# SITE SPECIFIC LISTERIA INTEGRATION VECTORS AND METHODS FOR USING THE SAME

## ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

5

This invention was made with Government support under Grant Nos. 1 R37 AI29619 and 1 R01 AI27655 awarded by the National Institute of Health. The Government has certain rights in this invention.

10

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application serial no. 10/136,860 filed April 30, 2002; the disclosure of which is herein incorporated by reference.

15

## INTRODUCTION

### Field of the Invention

The field of this invention is *Listeria* species, e.g., *Listeria monocytogenes*, particularly recombinant strains of *Listeria* species, and methods for their  
20 fabrication and use.

### Background of the Invention

*Listeria monocytogenes* is a Gram-positive, food-borne human and animal pathogen responsible for serious infections in immunocompromised individuals and pregnant women. Severe *L. monocytogenes* infections in humans are  
25 characterized by meningitis, meningoencephalitis, septicemia, and fetal death. *L. monocytogenes* is ubiquitous in nature and, in addition, can be isolated from a wide variety of warm blooded animals.

Protocols for recombinantly engineering *Listeria* species are of interest in both research and therapeutic applications. For example, *Listeria* species  
30 transformation protocols find use in the elucidation of the mechanisms responsible for growth and virulence of these types of bacteria. In addition, such protocols also find use in the preparation of live *Listeria* vaccines, which vaccines find use in a variety of different medical applications.

To date, a variety of different protocols have been employed to transform *Listeria* species, where such protocols include: homologous recombination, transposon based recombination, etc. While different protocols are currently available for engineering *Listeria* species, such methods are not entirely  
5 satisfactory. Disadvantages currently experienced with one or more of the available protocols include: (1) instability of the expression cassette in the transformed species; (2) variable impact on virulence of the transformed species; (3) size constraints of the expression cassette that can be placed in the transformed species; etc.

10 As such, despite the variety of different transformation protocols available, there is continued interest in the identification of further transformation protocols that can expand the repertoire of available genetic tools. Of particular interest would be the development of an efficient, site-specific integration vector that was suitable for use with a wide array of different *Listeria* species, where the vector  
15 did not suffer from one or more of the above disadvantages of the currently available protocols.

#### Relevant Literature

Patents and published patent applications of interest include: U.S. Patent No. 5,830,702 and published PCT application serial nos.: WO 99/25376 and WO  
20 00/09733.

#### SUMMARY OF THE INVENTION

Site-specific *Listeria* species integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage  
25 that is source of these elements is a listeriphage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a coding sequence, e.g., a coding sequence for a heterologous polypeptide, etc. The subject vectors and methods find use in a variety of different applications, including the study of *Listeria* species and the  
30 preparation of *Listeria* species vaccines.

#### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. (A) Plasmid map of the pPL1 integration vector. SEQ ID NO:24 provides the sequence of pPL1. Chloramphenicol resistance genes and *E. coli*

origin of replication are shown in grey, RP4 origin of transfer shown in white, integrase gene and *L. monocytogenes* p60 promoter shown in black. Multiple cloning site is shown at the bottom of the plasmid with unique restriction sites noted below the MCS in a box. pPL24 and pPL25 inserts are shown

- 5 schematically below the MCS and were cloned as described in Materials and Methods. Final sizes of the plasmid constructs and the restriction sites used in cloning are noted with each of the inserts. (B) Plasmid map of the integration vector pPL2. SEQ ID NO:28 provides the sequence of pPL2. The color scheme and genes are the same as in FIG. 1A except the PSA integrase and PSA $\text{attPP}$  sites as noted. The multiple cloning site with 13 unique restriction sites is shown at the bottom of the plasmid.

- FIG. 2. Genomic organization of the attachment sites within the *comK* gene (A and B) and the tRNA<sup>Arg</sup> gene (C and D). (A) Non-lysogenic *L. monocytogenes* strain, with an intact *comK* gene. Primers PL60 and PL61  
15 amplify across the bacterial attachment site *comK-attBB'*. (B) Lysogenic *L. monocytogenes* strain (with approximately 40 kb of phage DNA inserted into the *comK* gene) or integrated strain (with pPL1 construct inserted into the *comK* gene). Primers PL14 and PL61 amplify across the hybrid attachment site *comK-attPB'*. (C) *L. monocytogenes* serotype 4b strain non-lysogenic at tRNA<sup>Arg</sup>-*attBB'*.  
20 Primers NC16 and NC17 amplify across the bacterial attachment site tRNA<sup>Arg</sup>-*attBB'* in serotype 4b strains. Asterisk indicates primers NC16 and NC17 are substituted with PL102 and PL103 to amplify across the bacterial attachment site tRNA<sup>Arg</sup>-*attBB'* in serotype 1/2 strains. (D) Lysogenic *L. monocytogenes* strain (with approximately 40 kb of phage DNA or 6 kb pPL2 vector DNA inserted at the  
25 3' end of the tRNA<sup>Arg</sup> gene. Primers NC16 and PL95 amplify across the hybrid attachment site tRNA<sup>Arg</sup>-*attBP'* in both serotype 4b and 1/2 strains.

- FIG. 3. Expression and functional complementation of ActA in SLCC-5764. (A) Coomassie blue stained SDS-PAGE of SLCC-5764 derived strains grown to late-log phase. ActA is indicated by an arrow. Lane 1: molecular size  
30 marker; lane 2: DP-L3780; lane 3: DP-L4083; lane 4: DP-L4086; lane 5: SLCC-5764; lane 6: DP-L4082; lane 7: DP-L4084; lane 8: DP-L4085; lane 9: DP-L4087. Strains are described in Table 1. (B) Actin tail formation and movement of DP-

L4087 in *Xenopus* cell extract. The top panel is a phase image; the bottom panel is a fluorescent image of the same field.

FIG 4. (A) Clover-leaf diagram of tRNA<sup>Arg</sup> utilized as the PSA attachment site. The arginine anticodon is circled. The region with sequence identity between the tRNA gene and the PSA *attPP'* is outlined. The boundaries of the tRNA<sup>Arg</sup> gene and Cove score (82.37) were predicted with tRNAscan-SE (31). (B) Alignment of the tRNA<sup>Arg</sup>-*attBB'* region of *L. monocytogenes* WSLC 1042 (top line) and the *attPP'* region of PSA downstream of the integrase gene. The 74 nt tRNA<sup>Arg</sup> gene of *L. monocytogenes* is boxed and the 17 bp overlapping region of sequence identity (core integration site) is shaded grey. The tRNA<sup>Arg</sup> gene anticodon is shown in bold and underlined. Identical nucleotide residues are indicated by (:). The numbers located at the left indicate the nucleotide position in the DNA sequences of the WSLC 1042 attachment site (AJ314913) and PSA genome (AJ312240).

15

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Site-specific *Listeria* species integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a coding sequence, e.g., for a heterologous polypeptide, etc. The subject vectors and methods find use in a variety of different applications, including the study of *Listeria* species and the preparation of *Listeria* species vaccines.

Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention.

The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, representative methods, devices and materials are now described.

All publications mentioned herein are incorporated herein by reference for the purpose of describing various invention components that are described in the publications which might be used in connection with the presently described invention.

In further describing the subject invention, the subject vectors are reviewed first in greater detail, followed by a review of the methods of using the subject vectors, as well as representative applications in which the subject vectors and methods find use.

## VECTORS

As summarized above, the subject invention provides *Listeria* site-specific integration vectors, i.e., vectors that integrate into *Listeria* genomes in a site-

specific manner. The subject vectors are characterized in that they stably integrate into a genome of a *Listeria* species in a site-specific, as opposed to random, manner. As the subject vectors integrate site-specifically into a target genome, the vectors of the subject invention typically are inserted into a specific  
5 location or sequence (i.e., domain, location) of the target genome by a mechanism mediated by a recombinase, specifically an integrase, where the integrase is one that uses two distinct recognition sites as substrates, one of which is positioned in the integration site of the target genome (the site into which a nucleic acid is to be integrated) and another adjacent a nucleic acid of interest  
10 to be introduced into the integration site (i.e., a site on the subject vector referred to herein as the "bacteriophage attachment site"). For example, the recognition sites for phage integrases are generically referred to as attB, which is present in the bacterial genome (into which nucleic acid is to be inserted) and attP (which is present in the phage nucleic acid adjacent the nucleic acid for insertion into the  
15 bacterial genome, which is referred to herein as the "bacteriophage attachment site"). Recognition sites can be native (endogenous to a target genome) or altered relative to a native sequence. Use of the term "recognize" in the context of an integrase "recognizes" a recognition sequence, is meant to refer to the ability of the integrase to interact with the recognition site and facilitate site-  
20 specific recombination.

The subject vectors are capable of integrating into the genomes of a wide variety of different *Listeria* species. Integration is readily determined by using any convenient assay, including those known to those of skill in the art, that can identify whether or not vector DNA has integrated into the genomic DNA of a  
25 target organism. For example, vector DNA can be introduced into a target organism, e.g., via conjugation, and then integration can be determined via PCR amplification of the integrated sequence using primers flanking the target site, where the size of the amplification product is determinative of whether integration has occurred. An example of such an assay is provided in the experimental  
30 section, below. Additional features of many embodiments of the subject vectors is that they replicate autonomously in a non-*Listeria* host cell, e.g., *E. coli*, and are stable and innocuous in such non-*Listeria* host cells.

The subject integration vectors are typically double-stranded plasmid vectors, where the vectors are generally at least about 3 kb, often at least about 5

kb and may be large as 15 kb, 20 kb, 25 kb, 30 kb or larger, where the vectors sometimes range in size from about 3-6 to about 20 kb. The vectors include a number of structural features that impart to the vectors the above-described functional characteristics.

5        One structural feature of the subject vectors is a bacteriophage integrase gene, i.e., a nucleic acid coding sequence for a bacteriophage integrase, which is operably linked to a *Listeria* specific promoter, such that the gene (coding sequence) is expressed in the *Listeria* cell for which the vector is designed to be employed. In many embodiments, the bacteriophage integrase gene is one  
10 obtained from a listeriophage, i.e., it is a listeriophage integrase gene. A variety of different listeriophages are known in the art, where any convenient listeriophage may serve as the source of the integrase gene, i.e., the integrase encoding nucleic acid. Specific integrases of interest include, but are not limited to: the U153 integrase, the PSA integrase; and the like.

15        As indicated above, the integrase gene is operably linked to a promoter (as well as regulatory and/or signal sequences, if necessary) that drives expression of the integrase gene when the vector is present in the *Listeria* cell for which the vector is designed and in which integration of the vector is desired. Any convenient promoter may be employed, where in certain embodiments the  
20 promoter is a *Listeria* specific promoter. Representative promoters of interest include, but are not limited to: the *Listeria* p60 promoter, the *Listeria actA* promoter, the *Listeria plcA* promoter, the *Listeria mpl* promoter, the *Listeria plcB* promoter, the *Listeria inlA* promoter; a heat shock promoter; and the like. Promoters may also include certain bacteriophage promoters such as the  
25 promoters for T7, Q $\beta$ , SP6 and the like if the strain of *Listeria* also expresses the cognate bacteriophage RNA polymerase. In addition to the integrase gene/promoter element described above, the subject vectors also include a phage attachment site, i.e., a sequence or domain of nucleotides that provide for a site-specific integration with a *Listeria* genome. Any convenient phage  
30 attachment site may be employed, where selection of the phage attachment site will depend, at least in part, on the desired integration location for the vector. Representative phage attachment sites of interest include, but are not limited to: the comK integration site (as described in greater detail in the experimental

section below); the tRNA<sup>Arg</sup> integration site (as described in greater detail in the experimental section below); and the like.

In addition, the subject vectors may include an origin of replication that provides for replication of the vector in a non-Listeria host cell, e.g., E.coli. This  
5 origin of replication may be any convenient origin of replication or ori site, where a number of ori sites are known in the art, where particular sites of interest include, but are not limited to: p15A; pSC101; ColEI; pUC; pMB9; and the like.

In addition, the subject vectors may include an origin of transfer site or element when convenient, e.g., when the vector is introduced in the target  
10 Listeria cell using a conjugation protocol, as described in greater detail below. Any convenient origin of transfer (oriT) may be employed, where representative origins of transfer of interest include, but are not limited to: RP4 oriT; RSF1010 oriT;  
and the like.

15 In addition, the subject vectors typically include at least one restriction endonuclease recognized site, i.e., restriction site, which is located on the vector at a location which is amenable to insertion of a heterologous gene/expression cassette. A variety of restriction sites are known in the art and may be present on the vector, where such sites include those recognized by the following restriction  
20 enzymes: *HindIII*, *PstI*, *Sall*, *AccI*, *HincII*, *XbaI*, *BamHI*, *SmaI*, *XmaI*, *KpnI*, *SacI*, *EcoRI*, *BstXI*, *EagI*, *NotI*, *SpeI* and the like. In many embodiments, the vector includes a polylinker or multiple cloning site, i.e., a closely arranged series or array of sites recognized by a plurality of different restriction enzymes, such as those listed above.

25 In certain embodiments, the subject vectors include at least one coding sequence, e.g., a coding sequence for heterologous polypeptide/protein coding sequence present in the multiple cloning site, e.g., as a result of using a restriction endonuclease site present in the multiple cloning site to insert the coding sequence into the vector, according to well known recombinant  
30 technology protocols. By "heterologous" is meant that the coding sequence encodes a product, e.g., a protein, peptide, polypeptide, glycoprotein, lipoprotein, or other macromolecule, that is not normally expressed in Listeria. In many embodiments, this coding sequence is part of an expression cassette, which provides for expression of the coding sequence in the Listeria cell for which the

vector is designed. The term "expression cassette" as used herein refers to an expression module or expression construct made up of a recombinant DNA molecule containing at least one desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked  
5 coding sequence in a particular host organism, i.e., the *Listeria* cell for which the vector is designed, such as the promoter/regulatory/signal sequences identified above, where the expression cassette may include coding sequences for two or more different polypeptides, or multiple copies of the same coding sequence, as desired. The size of the coding sequence and/or expression cassette that  
10 includes the same may vary, but typically falls within the range of about 25-30 to about 6000 bp, usually from about 50 to about 2000 bp. As such, the size of the encoded product may vary greatly, and a broad spectrum of different products may be encoded by the expression cassettes present in the vectors of this embodiment.

15 The nature of the coding sequence and other elements of the expression cassette may vary, depending on the particular application of the vector, e.g., to study *Listeria* species, to produce *Listeria* species vaccines, for cytosolic delivery of macromolecules, etc. For example, where the vectors are employed in the production of *Listeria* vaccines, the coding sequence may encode a heterologous  
20 antigen, where representative heterologous antigens of interest include, but are not limited to: (a) viral antigens, e.g., influenza np protein, HIV gag protein, HIV env protein or parts thereof, e.g., gp120 and gp41, HIV nef protein, HIV pol proteins, HIV reverse transcriptase, HIV protease, herpes virus proteins, etc., (b) malarial antigens; (c) fungal antigens; (d) bacterial antigens; (e) tumor and tumor  
25 related antigens; and the like. Due to the flexibility of the vector system, virtually any coding sequence of interest may be inserted. Where secretion of the product encoded by the expression cassette is desired, the expression cassette may include a coding sequence for a fusion protein of a selected foreign antigen and a protein that directs secretion, e.g., Listeriolysin O or PI-PLC; a signal sequence,  
30 such as hemolysin signal sequence, etc. Where the subject vectors are employed in the preparation of *Listeria* delivery vehicles, e.g., as described in PCT publication no. WO 00/09733 (the priority application of which is herein incorporated by reference); and Dietrich et al., *Nature Biotechnology* (1998) 16: 181-185, the heterologous polypeptide coding sequence may be a cytolysin, e.g.,

phospholipase, pore forming toxin, listeriolysin O, streptolysin O, perfringolysin O, acid activated cytolysins, phage lysins, etc. Other coding sequences of interest include, but are not limited to: cytokines, costimulatory molecules, and the like. As indicated above, the vector may include at least one coding sequence, where  
5 in certain embodiments the vectors include two or more coding sequences, where the coding sequences may encode products that act concurrently to provide a desired results.

In general, the coding sequence may encode any of a number of different products and may be of a variety of different sizes, where the above discussion  
10 merely provides representative coding sequences of interest.

#### METHODS OF PREPARING THE SUBJECT VECTORS

The vectors of the subject invention may be produced using any  
15 convenient protocol, including by standard methods of restriction enzyme cleavage, ligation and molecular cloning. One protocol for constructing the subject vectors includes the following steps. First, purified nucleic acid fragments containing desired component nucleotide sequences as well as extraneous sequences are cleaved with restriction endonucleases from initial sources.  
20 Fragments containing the desired nucleotide sequences are then separated from unwanted fragments of different size using conventional separation methods, e.g., by agarose gel electrophoresis. The desired fragments are excised from the gel and ligated together in the appropriate configuration so that a circular nucleic acid or plasmid containing the desired sequences, e.g. sequences corresponding  
25 to the various elements of the subject vectors, as described above is produced. Where desired, the circular molecules so constructed are then amplified in a host, e.g. *E. coli*. The procedures of cleavage, plasmid construction, cell transformation and plasmid production involved in these steps are well known to one skilled in the art and the enzymes required for restriction and ligation are  
30 available commercially. (See, for example, R. Wu, Ed., Methods in Enzymology, Vol. 68, Academic Press, N.Y. (1979); T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1982); Catalog 1982-83, New England Biolabs, Inc.; Catalog 1982-83, Bethesda Research Laboratories, Inc. An example of how to

construct a vector of the present invention is provided in the Experimental section, below.

## METHODS

5

Also provided by the subject invention are methods of using the above described *Listeria* site specific integration vectors to integrate a heterologous nucleic acid into a *Listeria* genome. In practicing the subject methods, a vector of the subject invention is introduced into a target *Listeria* cell under conditions  
10 sufficient for integration of the vector into the target cell genome to occur. Any convenient protocol for introducing the vector into the target cell may be employed.

Suitable protocols include: calcium phosphate mediated transfection; protoplast fusion, in which protoplasts harboring amplified amounts of vector are  
15 fused with the target cell; electroporation, in which a brief high voltage electric pulse is applied to the target cell to render the cell membrane of the target cell permeable to the vector; microinjection, in which the vector is injected directly into the cell, as described in Capecchi et al, Cell (1980) 22: 479; and the like. The above *in vitro* protocols are well known in the art and are reviewed in greater  
20 detail in Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press)(1989) pp16.30-16.55.

In certain embodiments, e.g., where direct introduction into the target *Listeria* cell does not provide optimal results, one representative method that may be employed is a conjugation method, which comprises: (a) introducing the  
25 vector into a non-*Listeria* host cell, e.g., *E.coli*; followed by (b) transfer of the vector from the non-*Listeria* host cell to the *Listeria* host cell, e.g., by conjugation. Introduction into the non-*Listeria* host cell may be accomplished using any of the protocols described above. For the conjugation step, any convenient protocol may be employed, where suitable protocols typically include combining the donor  
30 and acceptor cells in a suitable medium and maintaining under suitable conditions for conjugation and vector transfer to occur. Specific representative conditions are provided in the Experimental section below.

The above methods result in stable integration of the vector and any expression cassette carried thereby, e.g., that encodes a heterologous

protein/foreign antigen, into a target *Listeria* cell genome in a site specific manner. The subject methods find use with a wide variety of different *Listeria* species.

## 5 UTILITY

The above described vectors and methods of using the same find use in a variety of different applications, where representative applications include, but are not limited to: (a) research applications; (b) vaccine preparation applications; (c)

10 *Listerial* delivery vehicle preparation applications; and the like.

One type of application in which the subject vectors and methods of using may be employed is in research of *Listeria* species. For example, the subject vectors and methods allow simple and efficient strain construction and are widely useful in various strains used to study the intracellular life cycle of *L.*

15 *monocytogenes*. Additionally, the subject vectors and methods may be employed to produce stable merodiploid strains to allow refined copy number studies and studies of interactions within a protein through multimerization and testing of the dominance or recessive nature of different alleles of a gene in the same bacterial strain.

20 The subject vectors and methods also find use in vaccine preparation applications. For example, the subject vectors find use in the production of *Listeria* cultures capable of expressing a heterologous antigen, i.e., *Listeria* vaccines, where the *Listeria* cells employed may be attenuated. The attenuated strains employed may be capable of normal invasion of a host cell, but incapable  
25 of normal survival or growth in the cell or cell-to-cell spread, or they may have other alterations that preclude normal pathogenicity.

The vaccines produced using vectors of the present invention are administered to a vertebrate by contacting the vertebrate with a sublethal dose of the genetically engineered *Listeria* vaccine, where contact typically includes  
30 administering the vaccine to the host. Thus the present invention provides for vaccines genetically engineered with the integration vector and provided in a pharmaceutically acceptable formulation. Administration can be oral, parenteral, intranasal, intramuscular, intravascular, direct vaccination of lymph nodes, administration by catheter or any one or more of a variety of well-known

administration routes. In farm animals, for example, the vaccine may be administered orally by incorporation of the vaccine in feed or liquid (such as water). It may be supplied as a lyophilized powder, as a frozen formulation or as a component of a capsule, or any other convenient, pharmaceutically acceptable formulation that preserves the antigenicity of the vaccine. Any one of a number of well known pharmaceutically acceptable diluents or excipients may be employed in the vaccines of the invention. Suitable diluents include, for example, sterile, distilled water, saline, phosphate buffered solution, and the like. The amount of the diluent may vary widely, as those skilled in the art will recognize. Suitable excipients are also well known to those skilled in the art and may be selected, for example, from A. Wade and P.J. Weller, eds., *Handbook of Pharmaceutical Excipients* (1994) The Pharmaceutical Press: London. The dosage administered may be dependent upon the age, health and weight of the patient, the type of patient, and the existence of concurrent treatment, if any. The vaccines can be employed in dosage forms such as capsules, liquid solutions, suspensions, or elixirs, for oral administration, or sterile liquid for formulations such as solutions or suspensions for parenteral, intranasal intramuscular, or intravascular use. In accordance with the invention, the vaccine may be employed, in combination with a pharmaceutically acceptable diluent, as a vaccine composition, useful in immunizing a patient against infection from a selected organism or virus or with respect to a tumor, etc. Immunizing a patient means providing the patient with at least some degree of therapeutic or prophylactic immunity against selected pathogens, cancerous cells, etc.

The subject vaccines prepared with the subject vectors find use in methods for eliciting or boosting a helper T cell or a cytotoxic T-cell response to a selected agent, e.g., pathogenic organism, tumor, etc., in a vertebrate, where such methods include administering an effective amount of the Listeria vaccine. The subject vaccines prepared with the subject vectors find use in methods for eliciting in a vertebrate an innate immune response that augments the antigen-specific immune response. Furthermore, the vaccines of the present invention may be used for treatment post-exposure or post diagnosis. In general, the use of vaccines for post-exposure treatment would be recognized by one skilled in the art, for example, in the treatment of rabies and tetanus. The same vaccine of the present invention may be used, for example, both for immunization and to boost

immunity after exposure. Alternatively, a different vaccine of the present invention may be used for post-exposure treatment, for example, such as one that is specific for antigens expressed in later stages of exposure. As such, the subject vaccines prepared with the subject vectors find use as both prophylactic and  
5 therapeutic vaccines to induce immune responses that are specific for antigens that are relevant to various disease conditions.

The patient may be any human and non-human animal susceptible to infection with the selected organism. The subject vaccines will find particular use with vertebrates such as man, and with domestic animals. Domestic animals  
10 include domestic fowl, bovine, porcine, ovine, equine, caprine, Leporidate (such as rabbits), or other animal which may be held in captivity.

In general, the subject vectors and methods find use in the production of vaccines as described U.S. Patent No. 5,830,702, the disclosure of which is herein incorporated by reference; as well as PCT publication no WO 99/25376,  
15 the disclosures of the priority applications of which are herein incorporated by reference.

The subject vectors also find use in the production of listerial delivery vehicles for delivery of macromolecules to target cells, e.g., as described in: PCT publication no. WO 00/09733 (the priority application of which is herein  
20 incorporated by reference); and Dietrich et al., Nature Biotechnology (1998) 16: 181-185. A variety of different types of macromolecules may be delivered, including, but not limited to: nucleic acids, polypeptides/proteins, etc., as described in these publications.

#### KITS & SYSTEMS

25

Also provided are kits and systems that find use in preparing the subject vectors and/or preparing recombinant Listeria cells using the subject vectors and methods, as described above. For example, kits and systems for producing the subject vectors may include one or more of: an initial vector with a multiple  
30 cloning site; a restriction endonuclease for cleaving a site in the multiple cloning site, a vector including an expression cassette of interest which is to be inserted into the multiple cloning site; etc. Where the kits and systems are designed for the production of the recombinant Listeria cells, the kits and systems may include

vectors, or components for making the same, as described above, *Listeria* target cells, non-*Listeria* host cells, and the like. The subject kits may further include other components that find use in the subject methods, e.g., reaction buffers, growth mediums, etc.

- 5        The various reagent components of the kits may be present in separate containers, or may all be precombined into a reagent mixture for combination with template DNA.

In addition to the above components, the subject kits will further include instructions for practicing the subject methods. These instructions may be  
10 present in the subject kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc. Yet another means would be a computer readable medium,  
15 e.g., diskette, CD, etc., on which the information has been recorded. Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means may be present in the kits.

- 20        The following examples are offered by way of illustration and not by way of limitation.

## EXPERIMENTAL

### 25 I. MATERIALS AND METHODS

#### A. Construction of pPL1 integration vector.

Standard molecular techniques were used in the construction of the 6101 bp integration vector pPL1 (Fig. 1A). The complete sequence of the pPL1 vector  
30 is provided as SEQ ID NO:25. pPL1 is a low copy plasmid that replicates autonomously in *E. coli* and integrates in a site-specific manner in *L. monocytogenes*, and was assembled from 6 independent DNA sources as follows. Restriction sites in the PCR primers used for construction are

underlined. All PCR reactions used in cloning steps utilized Vent DNA polymerase (New England Biolabs).

- The multiple cloning site (MCS) from pBluescript KS- (Alting-Mees, M. A., and J. M. Short. 1989. pBluescript II: gene mapping vectors. Nucleic Acids Res. 17:9494.) (bp 1-171) was cloned after PCR with primers 5'-  
 5 GGACGTCATTAACCCTCACTAAAGG-3' and 5'-  
GGACGTCAATACGACTCACTATAGG-3' (SEQ ID NOS: 01 & 02). The low copy Gram-negative origin of replication and chloramphenicol acetyltransferase (CAT) gene from pACYC184 (Chang, A. C., and S. N. Cohen. 1978. Construction and  
 10 characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J. Bacteriol. 134:1141-1156.) (bp 172-2253) were cloned after PCR with primers 5'-GGACGTCGCTATTTAACGACCCTGC-3' and  
 5'-GAGCTGCAGGAGAATTACAACCTATATCGTATGGGG-3' (SEQ ID NOS: 03 & 04). For direct conjugation from *E. coli* to *L. monocytogenes*, the RP4 origin of  
 15 transfer (*oriT*) (Pansegrau, W., E. Lanka, P. T. Barth, D. H. Figurski, D. G. Guiney, D. Haas, D. R. Helinski, H. Schwab, V. A. Stanisich, and C. M. Thomas. 1994. Complete nucleotide sequence of Birmingham IncP alpha plasmids. Compilation and comparative analysis. J. Mol. Biol. 239:623-663) (bp 2254-2624) was cloned from plasmid pCTC3 (Williams, D. R., D. I. Young, and M. Young.  
 20 1990. Conjugative plasmid transfer from *Escherichia coli* to *Clostridium acetobutylicum*. J. Gen. Microbiol. 136:819-826) after PCR with primers 5'-  
GCACTGCAGCCGCTTGCCCTCATCTGTTACGCC-3' and 5'-  
CATGCATGCCTCTCGCCTGTCCCCTCAGTTCAG-3' (SEQ ID NOS: 05 & 06). The listeriphage U153 integrase gene and attachment site (*attPP*) (A. Nolte, P.  
 25 Lauer, and R. Calendar, unpublished; bp 2629-4127)(SEQ ID NO: 25 includes the sequences for these sites), that direct the site-specific integration of the plasmid were cloned after PCR with primers 5'-  
GTAGATCTTAACTTTCCATGCGAGAGGAG-3' and 5'-  
GGGCATGCGATAAAAAGCAATCTATAGAAAAACAGG-3' (SEQ ID NOS: 07 & -  
 30 08). For expression of the U153 integrase gene, the *L. monocytogenes* p60 promoter (Lauer, P., J. A. Theriot, J. Skoble, M. D. Welch, and D. A. Portnoy. 2001. Systematic mutational analysis of the amino-terminal domain of the *Listeria monocytogenes* ActA protein reveals novel functions in actin-based motility. Mol. Microbiol. 42:1163-1177.) was PCR amplified with primers 5'-

CCTAAGCTTTCGATCATCATAATTCTGTC-3' and 5'-

GGGCATGCAGATCTTTTTTTCAGAAAATCCCAGTACG-3' (SEQ ID NOS: 09 &

10) and cloned upstream of the integrase gene. Base pairs 4570-6101 are a *Hind* III-*Aat* II restriction fragment subcloned from pUC18-Cat (a kind gift from Nancy Freitag), and contain the inducible Gram-positive CAT gene from pC194 (Horinouchi, S., and B. Weisblum. 1982. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. J. Bacteriol. 150:815-825) (bp 4788-5850).

#### 10 B. Cloning of the *hly* and *actA* genes into pPL1.

The *hly* gene was subcloned from the plasmid pDP-906 (Jones, S., and D. A. Portnoy. 1994. Characterization of *Listeria monocytogenes* pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect. Immun. 62(12):5608-5613.) by restriction digestion with *Bam*H I and *Xba* I, gel purifying a 2.9 kb fragment and by ligating it into pPL1 cut with *Bam*H I and *Spe* I. The resultant plasmid was designated pPL24 (Fig. 1A). The *actA* gene was PCR amplified from 10403S genomic DNA with primers 5'-GGTCTAGATCAAGCACATACCTAG-3' and 5'-CGGGATCCTGAAGCTTGGGAAGCAG-3' (SEQ ID NOS:11 & 12). The 2220 bp PCR product was gel purified, cut with *Bam*H I and *Xba* I, and cloned into pPL1 cut with *Bam*H I and *Spe* I. The resultant plasmid was designated pPL25 (Fig. 1A).

#### 25 C. Phage curing, conjugation and molecular confirmation of plasmid integration.

Phage curing was accomplished by adapting historical methodologies (Cohen, D. 1959. A variant of Phage P2 Originating in *Escherichia coli*, strain B. Virology 7:112-126; Six, E. 1960. Prophage substitution and curing in lysogenic cells superinfected with hetero-immune phage. J. Bacteriol. 80:728-729.). *L. monocytogenes* 10403S derivatives carrying a prophage at *comK-attBB'* (integrated in the *comK* ORF as described (Loessner, M. J., R. B. Inman, P. Lauer, and R. Calendar. 2000. Complete nucleotide sequence, molecular analysis and genome structure of bacteriophage A118 of *Listeria monocytogenes*: implications for phage evolution. Mol. Microbiol. 35(2):324-

340.)) were grown in BHI at 37°C to 10<sup>8</sup> CFU/ml and infected with listeriphage U153 (Hodgson, D. A. 2000. Generalized transduction of serotype 1/2 and serotype 4b strains of *Listeria monocytogenes*. Mol. Microbiol. 35(2):312-323.) at a multiplicity of infection of 20:1 in the presence of 5 mM CaCl<sub>2</sub>. Cultures were  
5 incubated by shaking at 37°C for 75 minutes and inhibition of growth was monitored by comparison of the OD<sub>600</sub> of the infected culture with an uninfected control culture. The infected culture was diluted 10<sup>-2</sup> and 10<sup>-4</sup> in BHI, and both dilutions were grown at 37°C until the 10<sup>-2</sup> dilution had increased 100-fold in optical density. The 10<sup>-4</sup> fold dilution was then diluted 10<sup>-2</sup>, and 3 µl were plated  
10 on BHI. Fifty colonies were tested for phage release initially by toothpicking colonies into 0.25 ml LB broth and replica plating at 30°C on a lawn of Mack-4R (DP-L862), a non-lysogenic rough strain of *L. monocytogenes* particularly susceptible to forming plaques. Candidates that did not plaque were then tested by spotting 10 µl of culture on a lawn of Mack-4R to detect plaque formation. If  
15 this second test was negative, the candidate was tested whether it could support plaque formation by the phage from the parent 10403S strain (Φ10403, (Hodgson, D. A. 2000. Generalized transduction of serotype 1/2 and serotype 4b strains of *Listeria monocytogenes*. Mol. Microbiol. 35(2):312-323.)). Curing was confirmed molecularly by PCR with the *comK-attBB'* specific primer pair  
20 PL60/PL61 (sequences follow) for the absence of a phage at *comK-attBB'*. Approximately 10% of colonies were cured using this procedure.

Recipient strains of *L. monocytogenes* (SLCC-5764, DP-L1169 and DP-L1172) were made streptomycin resistant for counter-selection in conjugation experiments by plate selection on BHI supplemented with 200 µg/ml antibiotic.  
25 pPL1 plasmid constructs were electroporated into *E. coli* strain SM10 (Simon, R., U. Priefer, and A. Pühler. 1983. A broad host range mobilization system for *in vitro* genetic engineering: transposon mutagenesis in Gram negative bacteria. Bio/Technology 1:784-791.) using standard techniques (Sambrook, J., T. Maniatis, and E. F. Fritsch. 1989. Molecular Cloning : A  
30 Laboratory Manual, 2nd edn. ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Bacterial strains were grown to mid-log (OD<sub>600</sub> ~0.55) shaking at 30°C. *E. coli* donor strains were grown in LB containing 25 µg/ml of chloramphenicol, *L. monocytogenes* recipient strains were grown in BHI. 2.5 ml

of donor culture was mixed with 1.5 ml of recipient culture and filtered onto pre-washed 47 mm 0.45 µm HA type filters (Millipore). The filter was washed once with 10 ml BHI, transferred to a BHI plate with no antibiotics and incubated for 2 hours at 30°C. The bacterial cells were gently resuspended in 2.5 ml of BHI and 5 25 µl and 50 µl aliquots were plated in 3 ml of LB top agar on BHI plates supplemented with 7.5 µg/ml chloramphenicol and 200 µg/ml streptomycin. Plates were incubated at 30°C overnight and shifted to 37°C for 2-3 days. Individual colonies were picked and screened by PCR for integration at the phage attachment site using the primers PL14 (5'-CTCATGAACTAGAAAAATGTGG-3') 10 (SEQ ID NO:13), PL60 (5'-TGAAGTAAACCCGCACACGATG-3')(SEQ ID NO:14) and PL61 (5'-TGTAACATGGAGGTTCTGGCAATC-3')(SEQ ID NO:15). PCR reactions were performed on small portions of individual bacterial colonies picked with sterile P200 pipet tips from BHI plates directly into 20 µl PCR reactions. The primer pair PL14/PL61 specifically amplifies *attBP'* in a PCR reaction, resulting in 15 a 743 bp product on integrated strains (both prophage and pPL1 derivatives). The primer pair PL60/PL61 specifically amplifies *comK-attBB'* in a PCR reaction, resulting in a 417 bp product only on non-lysogenic strains (i.e. DP-L4056). PCR assays were performed in a Hybaid Omn-E thermocycler with an annealing temperature of 55°C for 30 cycles. Integrants arose at a frequency of 20 approximately  $2 \times 10^{-4}$  per donor cell.

#### **D. Hemolysis on blood plates and hemolytic activity assay.**

Hemolysis on blood plates was scored on tryptic soy agar plates supplemented with 5% defibrinated sheep blood (HemoStat, Davis CA). 25 Hemolytic assays were performed essentially as described (Portnoy, D. A., P. S. Jacks, and D. J. Hinrichs. 1988. Role of hemolysin for the intracellular growth of *Listeria monocytogenes*. J. Exp. Med. 167(4):1459-1471.). Hemolytic activity is expressed as the reciprocal of the dilution of culture supernatant required to lyse 50% of sheep erythrocytes.

30

#### **E. Plaquing in L2 cells.**

Plaque sizes were determined as previously described (Lauer, P., J. A. Theriot, J. Skoble, M. D. Welch, and D. A. Portnoy. 2001. Systematic mutational

analysis of the amino-terminal domain of the *Listeria monocytogenes* ActA protein reveals novel functions in actin-based motility. Mol. Microbiol. 42(5):1163-1177.). Each strain was plaqued in 6 to 8 independent experiments and compared to 10403S in each experiment.

5

**F. SDS-PAGE of surface expressed ActA.**

Surface expressed ActA protein was prepared from late-log phase bacterial cultures grown in LB broth (OD<sub>600</sub> ~0.7) by resuspending equivalent amounts in SDS-PAGE buffer and boiling for 5 min. which extracts surface-  
10 expressed proteins but does not perturb the cell wall. Equivalent amounts were loaded on 7% SDS-PAGE and visualized with Coomassie blue.

**G. *Xenopus laevis* cell extract motility assays.**

*X. laevis* egg cytoplasmic extract was prepared as described (Theriot, J. A., J. Rosenblatt, D. A. Portnoy, P. J. Goldschmidt-Clermont, and T. J. Mitchison. 1994. Involvement of profilin in the actin-based motility of *L. monocytogenes* in cells and in cell-free extracts. Cell 76(3):505-517.) and supplemented with tetramethylrhodamine iodoacetamide-labeled actin (Theriot, J. A., and D. C. Fung. 1998. *Listeria monocytogenes*-based assays for actin assembly factors. 20 Methods Enzymol. 298:114-122.). SLCC-5764-derived strains were grown overnight to stationary phase, washed 1x, added to cell extracts and incubated for 45 minutes before microscopic observation.

**H. LD<sub>50</sub> determinations.**

25 Limited LD<sub>50</sub> were performed in BALB/c mice as described (Portnoy, D. A., P. S. Jacks, and D. J. Hinrichs. 1988. Role of hemolysin for the intracellular growth of *Listeria monocytogenes*. J. Exp. Med. 167(4):1459-1471.). Animal experiments were performed in the laboratory of Archie Bouwer at Oregon Health Sciences Center, Portland, OR.

30

**I. Identification of the PSA attachment site and construction of pPL2.**

The PSA attachment site (tRNA<sup>Arg</sup>-attBB') DNA sequence was obtained through a combination of inverse PCR and genome walking. Inverse PCR was

performed on *Sau*3 AI-digested DP-L4061 DNA (WSLC 1042 lysogenic for PSA) (SEQ ID NO:26 is the sequence of 2,072 bp surrounding WSLC 1042 tRNA<sup>Arg</sup>-*attBB*) using the divergent primers PL95 (5'-ACATAATCAGTCCAAAGTAGATGC)(SEQ ID NO:16) and PL97 (5'-ACGAATGTAAATATTGAGCGG) (SEQ ID NO:17) that anneal within the PSA *int* gene. The resultant DNA sequence was used to design further oligonucleotides and these were used with the Genome Walker kit (Clontech), per the manufacturer's recommendations. DNA sequence and tRNA analysis was done with using MacVector (Accelrys), DNAsis (Hitachi), BLAST algorithm (2), and tRNAscan-SE (Lowe, T. M., and S. R. Eddy. 1997. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res.* 25(5):955-964.).

pPL1 was modified to utilize a different attachment site on the *L. monocytogenes* chromosome by replacing the U153 integrase gene and attachment site in the plasmid. The PSA *int* and *attPP'* were PCR amplified from PSA genomic DNA with primers PL100 (5'-GAAGATCTCCAAAAATAACAGGTGGTGG) (SEQ ID NO:18) and PL101 (5'-CATGCATGCGTGGAGGGAAAGAAGACGC) (SEQ ID NO:19) with Vent DNA polymerase, digested with *Bgl* II and *Sph* I, and ligated to pPL1 that had been digested with the same enzymes. The resultant plasmid was designated pPL2 (FIG 1B). The sequence of pPL2 is provided as SEQ ID NO:28.

The DNA sequence of the PSA tRNA<sup>Arg</sup>-*attBB'* from serotype 1/2 *L. monocytogenes* strains was obtained by a plasmid-trap strategy. DP-L4211 (pPL2 integrated in 10403S) genomic DNA was digested with *Nsi* I and *Nhe* I, which do not cleave in the vector, and ligated under dilute conditions to promote self-ligation. The ligations were transformed into XL1-blue and chloramphenicol resistant colonies were selected. The plasmids obtained were sequenced with the convergent primers PL94 (5'-GGAGGGAAAGAAGACGC) (SEQ ID NO:20) and PL95 (sequence above) for *attPB'* and *attBP'*, respectively, which flank *attPP'* in the PSA genomic DNA sequence. Further, because of the divergence between the sequences downstream of the tRNA<sup>Arg</sup> gene among serotypes, a serotype 1/2 specific PCR assay across tRNA<sup>Arg</sup>-*attBB'* was developed from the 10403S DNA sequence and used to determine the prophage status of various *L.*

*monocytogenes* strains. Primers PL102 (5'-TATCAGACCTAACCCAAACCTTCC) (SEQ ID NO:21) and PL103 (5'-AATCGCAAAATAAAAATCTTCTCG) (SEQ ID NO:22) specifically amplify a 533 bp PCR product in non-lysogenic serotype 1/2 strains. The primer pair NC16 (5'-GTCAAAACATACGCTCTTATC) (SEQ ID NO:23) and PL95 specifically amplify a 499 bp PCR product in strains that are either lysogenic or contain an integration vector at tRNA<sup>Arg</sup>-attBB'. (SEQ ID NO:27 provides the 643 bp surrounding 10403S tRNA<sup>Arg</sup>-attBB')

## 10 II. RESULTS AND DISCUSSION

### A. pPL1 forms stable, single-copy integrants in various *L. monocytogenes* strains.

pPL1 is the first shuttle integration vector that we constructed to facilitate strain construction in *L. monocytogenes*. In order to test the pPL1 vector, we needed a *L. monocytogenes* strain that did not have a phage at the *comK* bacterial attachment site. We adapted historical methods to cure *L. monocytogenes* strains of their prophages and found after superinfection with phage U153, which has the same attachment site as the endogenous 10403S prophage, we were able to isolate prophage-free strains (see Materials and Methods). The prophage-cured 10403S strain was designated DP-L4056 and was used in subsequent experiments.

Conjugation was chosen as a method for introducing the vector into the target cells, as many *Listeria* spp. are inefficiently transformed. Conjugation of pPL1 from *E. coli* into *L. monocytogenes* was successful. Drug resistant transconjugants arose at a reproducible frequency of  $\sim 2 \times 10^{-4}$  per donor *E. coli* cell, approximately three-fold lower than conjugation with autonomously replicating plasmids, indicating  $\sim 30\%$  integration efficiency for strains receiving the plasmid by conjugation. All chloramphenicol resistant colonies were positive with the PCR assay using primers PL14 and PL61 and negative using a PCR assay across attPP' in pPL1 (PL14 paired with a primer in the RP4 *oriT*) indicating that they were true integrants and that the full genetic complement of plasmid pPL1 had integrated into the *Listeria* chromosome. In addition, this

experiment demonstrated that pPL1 was not maintained as an episomal plasmid and that the vector did not integrate as a concatamer.

We tested the stability of the integrants under non-selective growth conditions. Three integrant strains, DP-L4074 and the merodiploid strains DP-L4076 and DP-L4078 (described in the following sections) were passed in liquid BHI media for 100 generations and plated for single colonies. Ninety-six colonies were then exposed to 0.1 µg/ml chloramphenicol (to induce CAT gene expression) and patched on plates containing 7.5 µg/ml antibiotic. All colonies retained drug resistance. Thirty colonies from each non-selective growth experiment were assayed with the PL14/PL61 PCR assay and all PCR reactions resulted in the 743 bp product, indicating all transconjugants retained the integrated plasmid.

We further addressed whether the integration vector would be generally useful for any *L. monocytogenes* strain with an available attachment site. There have been greater than 320 listeriophages isolated, and many have restricted host ranges. It was unclear whether there was a biological barrier to U153 integrase gene function in host strains that do not support U153 infection. We therefore picked three strains that did not contain a prophage at the *comK* attachment site; two serotype 4b clinical isolates and SLCC-5764, a serotype 1/2a strain that constitutively expresses the known virulence factors in an unregulated manner and has been useful for studying these virulence factors *in vitro*. Each of these strains was first made streptomycin resistant for counter selection in conjugation experiments (as described in Materials and Methods). Streptomycin resistant derivatives were chosen on the basis of having the same growth rate as the parent strain to avoid experimental complications related to viability. The resultant strains, DP-L4088, DP-L4089, and DP-L4082 all proved suitable recipients for pPL1 integration at a similar frequency to DP-L4056.

Finally, we conducted a survey of *L. monocytogenes* isolates to identify suitable strains that do not harbor a prophage at the *comK* attachment site using the PCR assays across *comK-attBB'* (primers PL60/PL61) and the hybrid *attPB'* (primers PL14/PL61). The results of these experiments (Table 2) indicated many of the strains commonly used to study the biology and pathogenesis of *L. monocytogenes* including 10403S, L028, and EGDe had a prophage at *comK*.

Table 2. Prophage status of various strains

Strain	Description	Source	serotype	PL60/PL61	PL14/PL61
				<i>comK</i>	<i>attPB'</i>
10403S	wild type	rabbit pellets	1/2a	- <sup>a</sup>	+
DP-L4056	10403S phage cured	This work	1/2a	+ <sup>b</sup>	-
DP-L861	SLCC-5764 (Mack)	WT (overexpresser)	1/2a	+	-
DP-L3818	WSLC 1118::A118	Camembert cheese	4b	-	+
DP-L3633	EGDe	WT (1960s human)	1/2a	-	+
DP-L3293	LO28	WT (clinical origin)	1/2c	-	+
DP-L185	F2397	L.A., Jalisco cheese	4b	+	-
DP-L186	ScottA	Massachusetts outbreak, milk	4b	+	-
DP-L188	ATTC 19113	Denmark, human	3	+	-
DP-L1168	clinical	cole slaw	4b	+	-
DP-L1169	clinical	patient	4b	+	-
DP-L1170	clinical	patient	4b	+	-
DP-L1171	clinical	brie	1/2b	+	-
DP-L1172	clinical	alfalfa tablets	4b	+	-
DP-L1173	clinical	deceased patient	4b	-	+
DP-L1174	clinical	deceased patient	4b	-	+
DP-L3809	1981 Halifax	placenta	4b	+	-
DP-L3810	1981 Halifax	CSF & brain	4b	+	-
DP-L3812	1981 Halifax	coleslaw	4b	+	-
DP-L3813	1996 Halifax	blood	?	-	+
DP-L3814	1981 Halifax	CSF	4b	+	-
DP-L3815	1993 Halifax	CSF	1/2a	+	-
DP-L3816	1995 Halifax	blood	?	+	-
DP-L3817	1993 Halifax	CSF	1/2a	+	-
DP-L3862	1998 Michigan	patient	4b	-	+

<sup>a</sup> (-): negative PCR result for primer pair noted at top of column. <sup>b</sup> (+): positive PCR result for primer pair noted at top of column. The PL60/PL61 primer pair specifically amplify a 417 bp PCR product in non-lysogenic strains and result in no PCR product in lysogenic strains. The PL14/PL61 primer pair specifically amplify a 743 bp PCR product in lysogenic strains and result in no PCR product in non-lysogenic strains.

#### B. The status of *comK* did not affect the virulence of *L. monocytogenes*.

We next compared DP-L4056 and DP-L4074 to wild-type 10403S in standard virulence assays to determine if the presence of a prophage at *comK*, lack of prophage, or integration vector altered the virulence phenotypes. These three strains were assayed for LLO activity, ability to form plaques in monolayers of L2 cells, and for virulence in the mouse LD<sub>50</sub> assay (Table 3). All were indistinguishable from one another, strongly suggesting that the integrity of the *comK* ORF and the presence of pPL1 had no measurable impact on virulence.

Table 3. Complementation of *actA* and *hly*

Strain	Genotype	Hemolysis on blood plates	Hemolytic activity <sup>a</sup>	Plaque size <sup>b</sup>	LD <sub>50</sub> <sup>c</sup>
10403S	wild type	+	nd	100.(na)	~2x10 <sup>4</sup>
DP-L4056	10403S phage cured	+	97	101 (1.4)	<1x10 <sup>5</sup>
DP-L4074	DP-L4056 <i>comK</i> ::pPL1	+	98	99 (1.4)	<1x10 <sup>5</sup>
DP-L4027	DP-L2161 phage cured, $\Delta hly$	-	0	0 (0)	1x10 <sup>8</sup>
DP-L4075	DP-L4027 $\Delta hly$ , <i>comK</i> ::pPL24	+	99	97 (3.9)	<1x10 <sup>5</sup>
DP-L4076	DP-L4056 <i>comK</i> ::pPL24	+	198	96 (2)	nd
DP-L4029	DP-L3078 phage cured, $\Delta actA$	nd	nd	0 (0)	2x10 <sup>7</sup>
DP-L4077	DP-L4029 $\Delta actA$ , <i>comK</i> ::pPL25	nd	nd	86 (4)	<1x10 <sup>5</sup>
DP-L4078	DP-L4056 <i>comK</i> ::pPL25	nd	nd	72 (6.8)	nd

<sup>a</sup> Hemolytic units data shown is from one representative experiment. nd: not determined. <sup>b</sup> Plaque size is the average of 8 to 10 independent experiments and shown as a percent of wild type (defined as 100%). Standard deviations are shown in parentheses. na: not applicable. <sup>c</sup> LD<sub>50</sub>s of 10403S and  $\Delta hly$  (DP-L2161) were determined in (37), the LD<sub>50</sub> of the  $\Delta actA$  strain (DP-L1942, a smaller deletion within the *actA* ORF that does not support actin nucleation at the bacterial surface) was determined in (4).

10

### C. Full complementation of *hly* at the phage attachment site.

Listeriolysin-O (LLO), the gene product of *hly*, is a secreted pore-forming cytolysin that is responsible for escape from the membrane-bound vacuole when *L. monocytogenes* first enters a host cell. LLO is absolutely required for the intracellular life cycle of *L. monocytogenes* and virulence. LLO activity can be measured by hemolytic activity on red blood cells. *Hly* mutants fail to form plaques in monolayers of L2 cells and are 5 logs less virulent in the mouse LD<sub>50</sub> assay.

We cloned the *hly* structural gene into pPL1 and conjugated this plasmid from *E. coli* to phage-cured wild type and  $\Delta hly$  *L. monocytogenes* derivatives, resulting in DP-L4076 (an *hly* merodiploid) and DP-L4075 (*hly* only at the phage *comK-att* site). These strains were tested for hemolytic activity on blood plates, for the relative amount of hemolytic units secreted, ability to form a plaque in a

monolayer of L2 cells, and virulence in the mouse LD<sub>50</sub> assay (Table 3). The quantitative complementation of *hly* in the deletion strain background and the doubling of hemolytic units produced in the merodiploid strain indicate two things. First, gene expression is not *de facto* affected by ectopic expression at the *comK* chromosomal position. Second, the *hly* promoter is self-contained. Additionally, a two-fold increase in the amount of LLO is not deleterious to the virulence and intracellular life cycle of *L. monocytogenes*, at least as measured by plaquing.

**D. Complementation of *actA* at the phage attachment site approaches wild-type expression.**

ActA, a second major *L. monocytogenes* virulence factor, is responsible for commandeering host cell actin-cytoskeletal factors used for intracellular bacterial motility. ActA is also absolutely required for bacterial pathogenesis as mutants in *actA* are both unable to spread from cell-to-cell and form a plaque in a cell monolayer and are 3 logs less virulent than wild type. Additionally, ActA expression appears to be more complex than that of LLO: there are two promoters that drive *actA* expression. One is immediately upstream of the *actA* ORF and the second is in front of the *mpl* gene upstream of *actA*.

We constructed several strains to evaluate the complementation of *actA* at the phage attachment site. The first group included making second-site complemented (DP-L4077) and merodiploid (DP-L4078) strains in the 10403S background. These were assayed for plaque formation in an L2 monolayer (Table 3). Integrated ActA did not fully complement in this assay (plaque size of 86%) and the merodiploid strain formed an even smaller plaque (72% of wild type). We interpret these results to indicate that there may be a small contribution of the second promoter upstream of the *mpl* gene for optimal *actA* expression. Additionally, there appears to be a critical concentration of ActA on the surface of intracellular bacteria because two copies of *actA* (with 3 promoters driving expression) further decreases the ability to spread from cell to cell, presumably because there is too much ActA on the bacterial surface for optimal motility.

We further tested ActA complementation in the virulence gene over-expressing strain SLCC-5764. ActA is effectively expressed in this strain from the *comK-attBB'* site (Fig 3A, lane 9). Considering the plaquing data of 10403S

complemented *actA* strains, it may have been predicted that the merodiploid strain DP-L4085 would make more ActA than the parent strain. However, this was not observed: the parent strain, the complemented strain and the merodiploid strain all expressed similar levels of ActA (Fig 3A, lanes 5, 8, and 9). This observation was likely due to the complete lack of regulation and high level of constitutive expression of ActA in SLCC-5764. Additionally, DP-L4087 supports actin nucleation at the bacterial surface, actin tail formation and bacterial motility in cell extracts (Fig. 3B). The results of these cell-extract experiments indicate that the integration vector system for complementation will be useful for *in vitro* studies of *L. monocytogenes* motility, facilitating strain construction and placing various molecular constructs in different host strains for study in a desired set of assays. In particular, several alleles of *actA* that have unusual motility phenotypes have been transferred to the SLCC-5764  $\Delta actA$  strain using pPL1 and are currently being evaluated in cell extracts. The study of these mutants in the simplified cell-extract system should yield insights into the activities of poorly understood regions of the ActA protein.

The strains referenced above are provided in the following Table 1.

Strain	Relevant genotype or plasmid
<u><i>E. coli</i>:</u>	
SM10	Conjugation donor. <i>F- thi-1 thr-1 leuB6 recA tonA21 lacY1 supE44 Mu+C l- [RP4-2(Tc::Mu)] Km<sup>r</sup> Tra+</i>
XL1-Blue	Plasmid manipulations. <i>recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F'proAB lacI<sup>f</sup>Z <math>\Delta</math>M15 Tn10 (Tet<sup>r</sup>)]</i>
DP-E4067	Integration vector pPL1/SM10
DP-E4068	<i>hly</i> integration vector pPL24/SM10
DP-E4069	<i>actA</i> integration vector pPL25/SM10
DP-E4190	Integration vector pPL2/SM10
<u><i>L. monocytogenes</i>:</u>	
10403S	wild type
DP-L4056	10403S phage cured
DP-L4027	DP-L2161 phage cured, $\Delta hly$
DP-L4029	DP-L3078 phage cured, $\Delta actA$
DP-L4074	DP-L4056 <i>comK</i> ::pPL1
DP-L4075	DP-L4027 $\Delta hly$ , <i>comK</i> ::pPL24
DP-L4076	DP-L4056 <i>comK</i> ::pPL24
DP-L4077	DP-L4029 $\Delta actA$ , <i>comK</i> ::pPL25
DP-L4078	DP-L4056 <i>comK</i> ::pPL25
SLCC-5764	Virulence gene over expresser (Mack, DP-L861)
DP-L862	Mack-4R (SLCC-5764 rough isolate)
DP-L4082	SLCC-5764 <i>Str<sup>r</sup></i> derivative
DP-L3780	SLCC-5764 $\Delta actA$ (deletion of amino acids 7-633)

Strain	Relevant genotype or plasmid
DP-L4083	DP-L3780S (Str <sup>r</sup> derivative)
DP-L4084	DP-L4082, <i>comK</i> ::pPL1
DP-L4085	DP-L4082, <i>comK</i> ::pPL25
DP-L4086	DP-L4083, <i>comK</i> ::pPL1
DP-L4087	DP-L4083 $\Delta actA$ , <i>comK</i> :: <i>actA</i>
DP-L4088	DP-L1169S 4b strain, Str <sup>r</sup>
DP-L4089	DP-L1172S 4b strain, Str <sup>r</sup>
DP-L4090	DP-L4088, <i>comK</i> ::pPL1
DP-L4091	DP-L4089, <i>comK</i> ::pPL1
DP-L4199	EGDe, Str <sup>r</sup> derivative
DP-L4026	WSLC 1042, (ATCC 23074)
DP-L4061	WSLC 1042::PSA
DP-L4221	10403S, tRNA <sup>Arg</sup> ::pPL2

#### E. Phage PSA integrates into a tRNA<sup>Arg</sup> gene and pPL2 construction.

pPL1 integration into *L. monocytogenes* strains that harbour a prophage in the *comK* attachment site is hindered by the process of first having to cure the prophage from the host strain. To alleviate the need for the phage-curing step, the specificity of pPL1 integration was changed to that of the PSA prophage. PSA, (Phage from ScottA) is the prophage of *L. monocytogenes* strain ScottA, a serotype 4b strain that was isolated during an epidemic of human listeriosis. Using the PSA genomic DNA sequence, we identified an integrase-like ORF with a contiguous non-coding sequence that we predicted to contain the *attPP'* sequences. The PSA integrase sequence was then used to obtain the DNA sequence of PSA-*attBB'* from the PSA lysogenic strain DP-L4061 (see Materials and Methods). PSA was found to integrate in a tRNA<sup>Arg</sup> gene that is 88% identical to a tRNA<sup>Arg</sup> gene (*trnSL-ARG2*) from *B. subtilis*. The anticodon of the tRNA<sup>Arg</sup> gene is 5'UCU, the most commonly used arginine anticodon in *L. monocytogenes*. The PSA and bacterial attachment sites share 17 bp of DNA identity, and the tRNA<sup>Arg</sup>-*attBB'* contains a short nucleotide sequence that completes the tRNA<sup>Arg</sup> sequence that is interrupted by integration of PSA (Fig 4). The attachment site tRNA<sup>Arg</sup> gene is present only once in the genome of *L. monocytogenes* strain EGDe and apparently only once in the serotype 4b. This indicates that not only is the PSA integration site unique, but also that precise reconstitution of the gene upon integration (or excision) is likely required for survival of the cell.

pPL2 was constructed by replacing the U153 listeriphage integrase gene and attachment site in pPL1 with the PSA listeriphage integrase gene and attachment site. pPL2 was transformed into SM10 and the resulting strain was mated into 10403S, EGDe (carrying a streptomycin resistance mutation) and the serotype 4b strain DP-L4088. Chloramphenicol resistant transconjugants arose from each of these crosses at approximately  $2 \times 10^{-4}$  per donor cell, the same rate as pPL1 integration. Two recombinants from each cross were restreaked under drug selection and tested by PCR for the presence of PSA-*attBP* using primers NC16 and PL95. The expected 499 bp PCR product was obtained in each of the colonies tested, indicating pPL2 integrates into tRNA<sup>Arg</sup>-*attBB*' in both serotype 1/2 and 4b strains. We tested the stability of the integrated pPL2 in both EGDe and DP-L4088 strains with the same non-selective 100-generation experiment described for pPL1. Forty-nine colonies from each of the amplified cultures were tested for chloramphenicol resistance. The EGDe-derived strains retained 100% drug resistant colonies indicating complete stability of the integrants. In the case of the DP-L4088 integrant, two of the 49 colonies were chloramphenicol sensitive, suggesting a low level of excision can occur in this serotype 4b strain. In order to test whether precise excision had occurred, we PCR amplified across tRNA<sup>Arg</sup>-*attBB*' and sequenced the PCR products. The wild-type DNA sequence was obtained, indicating a precise excision event.

During the course of our PCR experiments, we noted a divergence between the tRNA<sup>Arg</sup>-*attPB*' sites from serotype 4b and serotype 1/2 *L. monocytogenes*. To determine nature of this divergence, we isolated and sequenced the tRNA<sup>Arg</sup>-*attBB*' site from 10403S (as described in Materials and Methods). We found that the sequence of *attPB*' in 10403S (3' of the tRNA<sup>Arg</sup> gene) is unrelated to that of the serotype 4b strain WSLC 1042. In contrast to this, the sequence of *attBP*' (5' of the tRNA<sup>Arg</sup> gene) in 10403S is 96-97% identical to the corresponding regions in *L. monocytogenes* serotype 4b strain WSLC 1042, the serotype 4b strain sequenced by TIGR, and the serotype 1/2a strain EGDe sequenced by the European *Listeria* Consortium. Thus, the bacterial *attBB*' sequences recognized by the PSA integrase are likely to encompass more of the *attB* DNA sequence than the *attB*' DNA sequence. Additionally, we tested the availability of the tRNA<sup>Arg</sup>-*attBB*' in the common

laboratory strains of *L. monocytogenes* with a PCR assay using primers PL102 and PL103. We found the tRNA<sup>Arg</sup> attachment site to be available in strains 10403S, EGEE, and L028 indicating that pPL2 may be readily utilized in these backgrounds for strain construction, complementation, and genetics studies  
5 without first curing endogenous prophages.

**F. Expression of Aquoria victoria GFP.**

A GFP coding sequence as described in United States Patent No. 5,777,079 (the disclosure of which is herein incorporated by reference), is cloned  
10 into plasmid pPL1, transferred into the genome of *L. monocytogenes*. The GFP coding sequence is amplified by polymerase chain reaction (PCR) and the PCR fragment is cloned into the multiple cloning site of pPL1. A suitable promoter, containing appropriate transcriptional elements and a translational leader sequence for expressing the GFP in *L. monocytogenes* are cloned at the 5' end  
15 of the GFP coding sequence such that they induce the expression of the GFP protein. The modified pPL1 plasmid constructs are electroporated into *E. coli* strain SM10 using standard techniques, and the modified pPL1 plasmid construct is conjugated into *L. monocytogenes* as described above. Recombinant *L. monocytogenes* are selected on BHI plates supplemented with 7.5 µg/ml  
20 chloramphenicol and 200 µg/ml streptomycin. Individual colonies are picked and screened by PCR for integration at the phage attachment site using the primers PL14 (5'-CTCATGAACTAGAAAAATGTGG-3') (SEQ ID NO:13), PL60 (5'-TGAAGTAAACCCGCACACGATG-3')(SEQ ID NO:14) and PL61 (5'-TGTAACATGGAGGTTCTGGCAATC-3')(SEQ ID NO:15). Cultures of  
25 recombinant *L. monocytogenes* are grown, prepared and screened for GFP.

**III. Utility of pPL1 and pPL2.**

The construction and characterization of the first single step site specific integration vectors for use in *L. monocytogenes* furthers the genetic tools  
30 available for the study of this pathogen. These vectors allow more facile strain construction than historic methods and are widely useful in various strains used to study the intracellular life cycle of *L. monocytogenes*. Additionally, stable merodiploid strains can be constructed to allow refined copy number studies and

studies of interactions within a protein through multimerization and testing of the dominance or recessive nature of different alleles of a gene in the same bacterial strain.

pPL1 and pPL2 are also useful for vaccine development, e.g., for at least  
5 enhancing, including both eliciting and boosting, an immune response to a target  
cells or cells, e.g., a foreign pathogen, etc. Several recombinant *L.*  
*monocytogenes* systems have been used to elicit cell-mediated immune  
responses in mice (Frankel, F. R., S. Hegde, J. Lieberman, and Y. Paterson.  
1995. Induction of cell-mediated immune responses to human immunodeficiency  
10 virus type 1 Gag protein by using *Listeria monocytogenes* as a live vaccine  
vector. J. Immunol. 155(10):4775-4782.; Goossens, P. L., G. Milon, P. Cossart,  
and M. F. Saron. 1995. Attenuated *Listeria monocytogenes* as a live vector for  
induction of CD8+ T cells in vivo: a study with the nucleoprotein of the  
lymphocytic choriomeningitis virus. Int. Immunol. 7(5):797-805; Ikonomidis, G., Y.  
15 Paterson, F. J. Kos, and D. A. Portnoy. 1994. Delivery of a viral antigen to the  
class I processing and presentation pathway by *Listeria monocytogenes*. J. Exp.  
Med. 180(6):2209-2218.; Shen, H., M. K. Slifka, M. Matloubian, E. R. Jensen, R.  
Ahmed, and J. F. Miller. 1995. Recombinant *Listeria monocytogenes* as a live  
vaccine vehicle for the induction of protective anti-viral cell-mediated immunity.  
20 Proc. Natl. Acad. Sci. USA 92(9):3987-3991.). One limitation with plasmid-based  
expression of recombinant proteins in *L. monocytogenes* is the stability of the  
plasmids *in vivo* (i.e. in the host animal) without selection. Additionally,  
chromosomal construction of strains expressing foreign antigens is time  
consuming. pPL1 and pPL2 alleviate both of these concerns.

25

It is evident from the above results and discussion that subject invention  
provides a number of advantages. The construction and characterization of the  
first single step site specific integration vectors for use in *L. monocytogenes* as  
30 described herein furthers the genetic tools available for the study of this  
pathogen. For example, the subject vectors and methods allow more facile strain  
construction than historic methods and are widely useful in various strains used  
to study the intracellular life cycle of *L. monocytogenes*. Furthermore, the subject  
invention provides important new tools for the production of vaccine preparations.

One limitation with plasmid-based expression of recombinant proteins in *L. monocytogenes* is the stability of the plasmids *in vivo* (i.e. in the host animal) without selection. Additionally, chromosomal construction of strains expressing foreign antigens is time consuming. The subject vectors and methods of use  
5 alleviate both of these concerns. As such, the present invention represents a significant contribution to the art.

All publications and patent application cited in this specification are herein incorporated by reference as if each individual publication or patent application  
10 were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

15 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

20

WHAT IS CLAIMED IS:

1. An integration vector capable of site-specific *Listeria* genome integration.
2. The integration vector according to Claim 1, wherein said integration  
5 vector is a plasmid.
3. The integration vector according to Claim 2, wherein said integration  
vector comprises a bacteriophage integrase gene and a bacteriophage  
attachment site.
- 10 4. The integration vector according to Claim 3, wherein said bacteriophage is  
a listeriophage.
5. The integration vector according to Claim 3, wherein said attachment site  
15 provides for integration at an integration site selected from the group consisting  
of: the comK integration site and the tRNA<sup>Arg</sup> integration site.
6. The integration vector according to Claim 1, wherein said integration  
vector further includes a multiple cloning site.
- 20 7. The integration vector according to Claim 6, wherein said integration  
vector further includes a coding sequence.
8. The integration vector according to Claim 7, wherein said coding sequence  
25 encodes a polypeptide.
9. The integration vector according to Claim 8, wherein said polypeptide is an  
antigen.
- 30 10. The integration vector according to Claim 1, wherein said integration  
vector is pPL1.
11. The integration vector according to Claim 1, wherein said integration  
vector is pPL2.

12. A method of transforming a *Listeria*, said method comprising:  
contacting said *Listeria* with an integration vector according to Claim 1  
under conditions sufficient for said integration vector to integrate into said  
5 *Listeria*'s genome.
13. A *Listeria* transformed with a vector according to Claim 1.
14. A method of eliciting or boosting a cellular immune response to an antigen  
10 in a subject, said method comprising:  
administering to said subject an effective amount of *Listeria* cells  
according to Claim 13.
15. The method according to Claim 14, wherein said *Listeria* cells are  
15 attenuated.
16. A vaccine comprising a strain of *Listeria* cells according to Claim 13,  
wherein said *Listeria* cells express a heterologous antigen.
- 20 17. The vaccine according to Claim 16, wherein said *Listeria* cells are  
attenuated.
18. A recombinant culture of *Listeria* cells according to Claim 13.
- 25 19. The recombinant culture according to Claim 18, wherein said *Listeria* cells  
are attenuated.
20. A kit for use in preparing a vector according to Claim 7, said kit  
comprising:  
30 a vector according to Claim 1; and  
at least one nuclease that cuts said vector at said multiple cloning site.
21. The kit according to Claim 20, wherein said kit further comprises a host  
cell.

22. A kit for use in preparing a cell according to Claim 13, said kit comprising:  
a vector according to Claim 1;  
at least one nuclease that cuts said vector at said multiple cloning site; and  
5 a Listeria cell.

24. A system for preparing a vaccine according to Claim 16, said system  
comprising:  
a vector according to Claim 1;  
10 at least one nuclease that cuts said vector at said multiple cloning site;  
a coding sequence for said heterologous antigen;  
and  
Listeria cells.

15

Figure 1.




Figure 2.




Figure 3.





Figure 4.



B.

352 AGTCCATTTCCTGATAGCTCAGCTGGATAGAGCAACGGCTCTAAGCCGTCGGTCGGGGGTTGGAATCCCTCTCAGGACCFAAATAGCTAT  
19228 TTACATAAAATGTTTGTGGTATTATTTGTGGTATATATATCTAAATGGCTTTATATCAGTGTCTGTTAATCCCTCTCAGGACGTTAAATAGTAA

## SEQUENCE LISTING

<110> The Regents of the University of California

<120> SITE SPECIFIC LISTERIA INTEGRATION  
VECTORS AND METHODS FOR USING THE SAME

<130> BERK-017WO

<150> 10/136,860

<151> 2002-04-30

<160> 28

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1

ggacgtcatt aaccctcact aaagg

25

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2

ggacgtcaat acgactcact atagg

25

<210> 3

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 3

ggacgtcgct atttaacgac cctgc

25

<210> 4

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 4

gagctgcagg agaattacaa cttatatcgt atgggg

36

<210> 5  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 5  
gcactgcagc cgcttgccct catctgttac gcc }

<210> 6  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 6  
catgcatgcc tctcgctgt cccctcagtt cag 33

<210> 7  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 7  
gtagatctta actttccatg cgagaggag 29

<210> 8  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 8  
gggcatgcga taaaaagcaa tctatagaaa aacagg 36

<210> 9  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 9  
cctaagcttt cgatcatcat aattctgtc 29

<210> 10  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 10  
gggcatgcag atcttttttt cagaaaatcc cagtacg 37

<210> 11  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 11  
ggtctagatc aagcacatac ctag 1

<210> 12  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 12  
cgggatcctg aagcttggga agcag 25

<210> 13  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 13  
ctcatgaact agaaaaatgt gg 22

<210> 14  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 14  
tgaagtaaac ccgcacacga tg 22

<210> 15  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 15  
tgtaacatgg aggttctggc aatc 24

<210> 16  
<211> 24  
<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 16

acataatcag tccaaagtag atgc

24

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 17

acgaatgtaa atattgagcg g

1

<210> 18

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 18

gaagatctcc aaaaataaac aggtggtgg

29

<210> 19

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 19

catgcatgcy tggagggaag gaagaacgc

29

<210> 20

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 20

ggagggaag aagaacgc

18

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 21

tatcagacct aacccaaacc ttcc

24

<210> 22  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 22  
aatcgcaaaa taaaaatctt ctcg

4

<210> 23  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 23  
gtcaaaacat acgctcttat c

21

<210> 24  
<211> 6101  
<212> DNA  
<213> Shuttle integration vector pPL1

<220>  
<221> misc\_feature  
<222> 3676  
<223> n = A,T,C or G

<400> 24  
gacgtcaata cgactcacta tagggcgaat tgggtaccgg gccccccctc gaggtcgacg 60  
gtatcgataa gcttgatata gaattcctgc agcccggggg atccactagt tctagagcgg 120  
ccgccaccgc ggtggagctc cagcttttgc tccctttagt gaggggtaat gacgtcgcta 180  
tttaacgacc ctgccctgaa ccgacgaccg ggtcgaattt gctttcgaat ttctgccatt 240  
catccgctta ttatcactta ttcaggcgta gcaccaggcg tttaagggca ccaataactg 300  
ccttaaaaaa attacgcccc gccctgccac tcacgcgagt actggtgtaa ttcattaagc 360  
attctgccga catggaagcc atcacagacg gcatgatgaa cctgaatcgc cagcggcatc 420  
agcaccttgc cgccttgcgt ataataattg cccatggtga aaacgggggc gaagaagttg 480  
tccatattgg ccacgtttta atcaaaactg gtgaaactca cccagggtat ggctgagacg 540  
aaaaacatat tctcaataaa cccttttaggg aaataggcca ggttttcacc gtaacacgcc 600  
acatcttgcg aatatatgtg tagaaactgc cggaaatcgt cgtggtattc actccagagc 660  
gatgaaaacg tttcagtttg ctcatggaaa acggtgtaac aagggtgaac actatcccat 720  
atcaccagct caccgtcttt cattgccata cgggaattccg gatgagcatt catcaggcgg 780  
gcaagaatgt gaataaaggc cggataaaac ttgtgcttat ttttctttac ggtctttaaa 840  
aaggccgtaa tatccagctg aacggtctgg ttataggtac attgagcaac tgactgaaat 900  
gcctcaaaat gttctttacg atgccattgg gatatatcaa cgggtgtata tccagtgatt 960  
tttttctcca ttttagcttc cttagctcct gaaaaatctc ataactcaa aaatacggcc 1020  
ggtagtgcac ttatttcatt atggtgaaag ttggaacctc ttacgtgccg atcaacgtct 1080  
catttttcgcc aaaagtggc ccagggtctc ccggtatcaa cagggaacac aggatttatt 1140  
tattctgcga agtgatcttc cgtcacaggt atttattcgg cgcaaagtgc gtcgggtgat 1200  
gctgccaaact tactgattta gtgtatgatg gtgtttttga ggtgctccag tggcttctgt 1260  
ttctatcagc tgtccctcct gttcagctac tgacgggggt gtgcgtaacg gcaaaagcac 1320  
cgccggacat cagcgctagc ggagtgtata ctggcttact atgttggcac tgatgagggt 1380  
gtcagtgaag tgcttcattg ggcaggagaa aaaaggctgc accggtgcgt cagcagaata 1440  
tgtgatacag gatataattc gcttcctcgc tcaactgactc gctacgctcg gtcgttcgac 1500  
tgccggcagc ggaatggct tacgaacggg gcggagattt cctggaagat gccaggaga 1560  
tacttaacag ggaagtgaga gggccgcggc aaagccgttt ttccataggc tccgcccccc 1620  
tgacaagcat cacgaaatct gacgtcctaa tcagtggtgg cgaaacccga caggactata 1680

aagataccag gcgtttcccc ctggcggctc cctcgtgcgc tctcctgttc ctgcctttcg 1740  
gtttaccggg gtcattccgc tgttatggcc gcgtttgtct cattccacgc ctgacactca 1800  
gttccgggta ggcagttcgc tccaagctgg actgtatgca cgaaccccc gttcagtcgg 1860  
accgctgcgc cttatccggt aactatcgte ttgagtccaa cccggaaaga catgcaaaag 1920  
caccactggc agcagccact ggtaattgat ttagaggagt tagtcttgaa gtcatgcgcc 1980  
ggttaaggct aaactgaaag gacaagtttt ggtgactgcg ctccctccaag ccagttacct 2040  
cggttcaaaag agttggtagc tcagagaacc ttcgaaaaac cgccctgcaa ggcgggtttt 2100  
tcgttttcag agcaagagat tacgcgcaga ccaaaacgat ctcaagaaga tcatcttatt 2160  
aatcagataa aatattttcta gatttcagtg caatttatct cttcaaatgt agcacctgaa 2220  
gtcagcccca tacgatataa gttgtaattc tccgcgcgtt gccctcatct gttacgccgg 2280  
cggtagccgg ccagcctcgc agagcaggat tcccgttgag caccgccagg tgcgaataag 2340  
ggacagtga gagggaacac ccgctcgcgg gtgggcctac ttcacctatc ctgcccggct 2400  
gacgccgttg gatacaccaa ggaaagtcta cacgaacctt ttggcaaaat cctgtatatc 2460  
gtgcgaaaaa ggatggatat accgaaaaaa tcgctataat gaccccgaag cagggttatg 2520  
cagcggaaaa gcgctgcgtt cctgctgttt tgtggaatat ctaccgactg gaaacaggca 2580  
aatgcaggaa attactgaac tgaggggaca ggcgagaggc atgcgataaa aagcaatcta 2640  
tagaaaaaca ggttactttt tatttataat tttagtttct cgattcgttt ccgtccaacg 2700  
agaaaaaacg aggaactaaa caatctaaat aaacaagcta ctagagccat tcaatagtaa 2760  
cttgttcacc gtcaatataa attttattaa ttagtgattt taaataaagt tgcttttctc 2820  
ggaaactcaa agagtcaaaa tcaactgttg ctaaatcagc taaattttct tgtatctttt 2880  
tatttttctt caattcttcg ttagcttcta tttgtgcttc ataataatta atttgagcat 2940  
cgatatacgc catcatagca tcaagtcttg aaacttcgta agaaccgctg atatataaat 3000  
caaatagccg tttctttttt acgtgttctg ttttaagttt ttcatTTaag ctatctaaatt 3060  
cgtcttcttt atctacattc ctagaagcga aactatagtt attcacgcga tcaataatta 3120  
attcctcgag tttgtcagct ctccaaattt tatttccaca tttttctagt tcatgagtat 3180  
gtttgtaagt cttgcaacta taatatctat aatgatattt ttttccgcgg gaaacagtat 3240  
cttttctccg atgaacaaaa cccaaccac attttccaca cactaccaa ttatttagca 3300  
acgatgctga atctctattc atatttggtt ttttaccat gcgagaaaaa atttcttgaa 3360  
ctcgataaaa ttgttctctt gaaataatag gctcatgaac accttttgta tgcactttat 3420  
ccgcataaga tacataacca cagtataaat cattagttag ccaattgttg taactgctat 3480  
atgatttcac tttgaatcct aattttttta gtctctctg taaagtggta atgctttttt 3540  
cttctcctcaa aatatcata atcatttgta attgttttgc ttcttcttca ttaatatata 3600  
atttagtatc tataacatca tagccgaatg ttctacctt tgtagtcgtt aaagggaagac 3660  
ctgcttcaat acgctnaatt ttccccatca ccatacgatc acgtatagtt tcgcgctcta 3720  
attgagcaaa tacggataat ataccaatca tcgcgcgccc aaatgggcta gaggtgtcaa 3780  
gagtttcaga caaactaaca aattctacat tgttttttaa gaagtattct tcaataagcg 3840  
ttatcgtatc tctttgtgag cgggaaagtc tatctaagcg atatacaaca acagcatcaa 3900  
tttcatgtaa tttacttagc atttcattta gtgcggggcg attcatgttt gaaccgctgt 3960  
atccgcgctc tatgaaaaa tcgtatacgt cccaatcctt cgagcggcac aaggctgtta 4020  
gcttttcagt ttgagcttgt atagagtaat tctctatttg ttcttgagta gatacgcgta 4080  
tataaatagc tgccttcatt tccgttctcc tctcgcagtg aaagttaaga tcttttttct 4140  
agaaaatccc agtacgtaat taagtatttg agaattaatt ttatattgat taatactaag 4200  
tttaccagtt tttcacctaa aaaacaaatg atgagataat aactccaaag gctaaagagg 4260  
actataccaa ctatttgtaa taattctgta acagtggaaa agcgaacgtg tattcttagg 4320  
gcttgagatg tactgctggg taaaccttta tagtgtaagt gggatgtgaa cgttaatcaa 4380  
caactttcgc tatgggaaac ctattgtttt ttgttaatag aaaaacttaa tacatttgta 4440  
atataaaaa cggcagtttt tccgttcttc gtgactcgaa atgaattgcc agatgagttt 4500  
atggtattct ataatagaag gtatggagga tgttatataa tgagacagaa ttatgatgat 4560  
cgaagctag cttggcactg gccgtcgttt tacaacgctg tgactgggaa aaccctggcg 4620  
ttacccaact taatcgctt gcagcacatc cccctttcgc cagctggcgt aatagcgaag 4680  
aggccgcac cgtatgcct tcccaacagt tgcgcagcct gaatggcgaa tggcgccgta 4740  
tgcggtattt tctccttacg catctgtgcg gtatttcaca ccgcataatca aatggttcgg 4800  
atctggagct gtaatataaa aaccttcttc aactaacggg gcaggttagt gacattagaa 4860  
aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag tcattaggcc 4920  
tatctgacaa ttctgaata gaggttcataa acaatcctgc atgataacca tcacaaacag 4980  
aatgatgtac ctgtaaaagt agcggtaaat atattgaatt acctttatta atgaattttc 5040  
ctctgtaat aatgggtaga aggtaattac tattattatt gatatttaag ttaaaccccg 5100  
taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata ggtgttttgg 5160  
gaaacaattt ccccgacca ttatatttct ctacatcaga aagggtataaa tcataaaact 5220  
ctttgaagtc attctttaca ggagtccaaa taccagagaa tgttttagat acaccatcaa 5280  
aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg ctattgtaac 5340  
cagttctaaa agctgtattt gaggttatca cccttgcac taagaaaaa aatgcagggt 5400

```
aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca atttctgtgg 5460
ttatactaaa agtcgtttgt tggttcaa atgattaaa tatctctttt ctcttccaat 5520
tgcttaaatc aattttatta aagttcattt gatatgcctc ctaaaatttt atctaaagtg 5580
aatttaggag gcttacttgt ctgcttttct cattagaatc aatccttttt taaaagtcaa 5640
tattactgta acataaatat atattttaaa aatatccac tttatccaat tttcgtttgt 5700
tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt ggtcctttgt 5760
gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct tgataataag 5820
ggtaaactatt gccagatcc gaaccatttg atatggtgca ctctcagtag aatctgctct 5880
gatgccgcat agttaagcca gccccgacac ccgccaacac ccgctgacgc gccctgacgg 5940
gcttgctctgc tcccggcatc cgcttacaga caagctgtga ccgtctccgg gagctgcatg 6000
tgctcagaggt tttaccgctc atcaccgaaa cgcgcgagac gaaagggcct cgtgatacgc 6060
ctatttttat aggttaatgt catgataata atggtttctt a 6101
```

&lt;210&gt; 25

&lt;211&gt; 3897

&lt;212&gt; DNA

&lt;213&gt; Bacteriophage U153

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 695

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 25

```
aagcttttaa gaaattcaag aagaacatc ggtaactagc cataaattaa ccaaagttct 60
aatctcgctt gaagagaaca aactgattga aaaaattgga caatctagag caacaaaata 120
caaattaatt gaatctacag aggaatatct aaccaatctt caacacacat ttcgaaaaat 180
tgttcaattt tatgttgaaa atgataaata aaaatatgaa tgttttttta tttgtagta 240
gtgtaacttt ccatgcgaga ggagaacgga aatgaaggca gctatttata tacgcgtatc 300
tactcaagaa caaatagaga attactctat acaagctcaa actgaaaagc taacagcctt 360
gtgccgcctc aaggattggg acgtatacga tattttcata gacggcggat acagcggttc 420
aaacatgaat cgccccgcac taaatgaaat gctaagtaa ttacatgaaa ttgatgctgt 480
tgttgatat cgcttagata gactttcccg ctacacaaaga gatacgataa cgcttattga 540
agaatacttc ttaaaaaaca atgtagaatt tgtagtttg tctgaaactc ttgacacctc 600
tagcccatct gggcgcgaga tgattgggat attatccgta tttgctcaat tagagcgaga 660
aactatacgt gatcgtagg tgatgggaa aattnagcgt attgaagcag gtcttctctt 720
aacgactgca aaaggtagaa cattcggcta tgatgttata gatactaaat tatatattaa 780
tgaagaagaa gcaaaacaat tacaatgat ttatgatatt tttaggaag aaaaaagcat 840
taccacttta cagaagagac taaaaaaatt aggttcaaa gtgaaatcat atagcagtta 900
caacaattgg ctaactaatg atttatactg tggttatgta tcttatgcgg ataaagtga 960
tacaaaaggt gttcatgagc ctattatttc agaggaacaa ttttatcgag ttcaagaaat 1020
tttttctcgc atgggtaaaa atccaaatat gaatagagat tcagcatcgt tgctaaataa 1080
tttgtagtg tggtgaaaat gtgggttggg tttgttcat cggagaaaag atactgtttc 1140
ccgcggaaaa aaatatcatt atagatatta tagttgcaag acttacaac atactcatga 1200
actagaaaaa tgtggaaaata aaatttgag agctgacaaa ctcgaggaat taattattga 1260
tcgagtgaa aactatagtt tcgcttctag gaatgtagat aaagaagacg aattagatag 1320
cttaaatgaa aaacttaaaa cagaacacgt aaaaaagaaa cggctatttg atttatata 1380
cagcggttct tacgaagttt cagaacttga tgctatgat gctgatatcg atgctcaat 1440
taattattat gaagcacaaa tagaagctaa cgaagaattg aagaaaaata aaaagataca 1500
agaaaattta gctgatttag caacagttga ttttgactct ttagagttcc gagaaaagca 1560
actttattta aaatcactaa ttaataaaat ttatattgac ggtgaacaag ttactattga 1620
atggctctag tagcttgttt atttagattg tttagtctct cgttttctct cgttgacgg 1680
aaacgaatcg agaaactaaa attataaata aaaagtaacc tgtttttcta tagattgctt 1740
tttatcaatt atatagaaga aagccgcttt ttattagatt ataattgatg ttttttgatt 1800
tatatttcac tccctgtgca aataatgata taacagcaac ctcgaaactt ttagttcggg 1860
gtattttttt gaaattaatt tataaaaaa cttgcaatta tataatacat gtattataat 1920
ataaatatag aaaggagtgt agaaagtga agacatctta gaggaataa aaacagctct 1980
tgaaattgta actcttcag tagcgctgat aacattacgc aagatagaca aaaacaagga 2040
caagtaacca gaggggtgaa actccctccc ctctataaaa gtatatcacg tctttcataa 2100
attatgaata aatatatctg ggttatatta attgttatat gcgttaacgg actcgtagt 2160
tactttcaga acacagcatt gaccatcatt gctatactga ctacattagc ttgtttagta 2220
tatttaataa aaaataggaa gtgattaatt atgacgaaaa aaacgacctc tgacgcgcag 2280
ttgaaagcaa ataaggaaat gcaaaagaa aacaaagaa atgcaaaacta tttaaaatct 2340
```

cggttcagctg cgcggttcttt tataaagaat aaagctacgt tggaagattt gaaggaactt 2400  
gaaaaaatata ttatagaggg aaaaattaat cataagggaa tgattaagga taaatgatgc 2460  
acgctaagca catgcttgcc gttttttgca taaaaaaagc cctaacgttg aagttaggga 2520  
ctgacatata taaaaaatag aagttgacaa ctttaaggcg actaccacga caggcagctt 2580  
acaagctatg actagccttg actaatcatt tatgcgacac tcaaagaatt attatctaac 2640  
ttcttaataca agaataacaa aaatcaaaaca agttagcaag tatttcaggc attttattta 2700  
taacaaatat ctagatcaca aaaaatgtcgc ggaaaaataa ggtcacaacc aatattacat 2760  
aaacttaaaaa gttctctatt tctcttatca ggtttatgtg ctgttacgtg atttctacat 2820  
actctaaaaa ctgtattagc gaataagtct acaacttgaa ttaaatcttt attttgtgaa 2880  
tccttatatg atgtttcaac agaagagaaa attggatgtt ccattgtaaa tttaatagtt 2940  
aaatattctt gtaagctatt taatgattca attgcggtat ttctatcatc tatttgcatt 3000  
ttcaaatagt tatttgcgtg gtttaattggg atttttagaaa ttctcattac cgtttagata 3060  
ataaaaataat taaaagacaa agatgtatta ttcaaaagat gattgactag ttggtgggta 3120  
tcgcatatct taaaatgaaa tttagcatct gattttgttg aaagcatatt aaatattaat 3180  
tttttctatt caaaaggcat ctccgaacct tttatctctt ttgtaatatc taacttacta 3240  
gatggatacc ttttaagata ttttaatttt gcatctctga actgtctaatt tacattatat 3300  
ggtttctctg tttctaaaaa agcaataaca aaatatctgt tattaaaaatt tttattttta 3360  
gttatagttc ctgattcatc tacaaaaagt ctcatcccg ttcctccact tttttactta 3420  
aatttatatta tactaattaa gtttgaggaa gtggaacgta tgtacttata attcgaagtt 3480  
atgaaaaatc ccccatcaa tataaaacaa aaaagcccc gaaataataa tcgagggcat 3540  
taaaactaat ctttttaaca aacttcggtg ttagcagtga gatagtaacc agatttcggt 3600  
ttcaagcgag gtgttcgcc ttttgttttc gccattcctg taatcgtgaa gatagtgcct 3660  
accggatatg tgccaccggt tttatgcttc tcagtaaagt ctactgaatt gtatagatca 3720  
cactgtacta gtgttttaac ttttcgcgga ttttctgtgt agtatgtgtt tttgctgtg 3780  
ggtgtgtgtg gttttctgc ttttaacttc gctaataatg ttgtgttctg cgttgctgtt 3840  
cctttataat ccttaattcc gtattgattt gctagttttt tacgattcgc aaagctt 3897

&lt;210&gt; 26

&lt;211&gt; 2702

&lt;212&gt; DNA

<213> *Listeria monocytogenes*

&lt;400&gt; 26

gatatcgcg acgtgaatta aacgcagatt ttgccttttt tggtcaccgg catgaactag 60  
gagtagacat gctagacgac accatcattt taaacccagg aagcatttcc ttaccaagag 120  
gacgcacccg tgtcaaaaca tacgctctta tcgattcaac accagaaggc attcaagttc 180  
gattcatgga ccgggacgac aacgaactaa cggacctaac ccaaaccctc ccattaacga 240  
agcataacta ggtcaaaaga cccccgaaaa agaaaaaatg caataactta aagaaaacca 300  
ttgacaaaaca agcgatttaa acataaaatg gtatttggct gttgaaaaaa cagtgccatt 360  
tgtcctgata gctcagctgg atagagcaac ggccttctaa gccgtcggtc ggggggtcga 420  
atccctctca ggacgtaaat agctatatta aagaaatctc taaaacgttg aaaaaccctg 480  
atattaaagg ttggatggat gtttttagaga tttttttata tcttataata tctgttttat 540  
tccgtatttt tcatgacatt tgtgacaaaa tttgtgctat ttccatccat ttttaattgtg 600  
aaaaaagcat ctattttagt ttgattatgt tgatgcaaat tagagcttag attattataa 660  
tatttttaatg ttattaatat caggttgacc tctcctaagt gttagacatg tttcaccagt 720  
ctccatagga gtgtggtagc tgattgcaca gtaattatat actttacgtc aatatcaaaa 780  
gcaagtccaa ttaaaatgga ttaccttgcc ccgtaaatga caacttctga aaataggtaa 840  
aaggaacaaa agatgatgta attagggtct agtgcatgtg tgggtgaattt aggttttgat 900  
tataatgaga atctccggtt agagggtgtt cttttgaaaa cgatagaagc aattataggt 960  
atcgactacc atattactac gaaaaaagag ctagattaaa taaaaaata attctaact 1020  
cataggagcg aattatgact tttttaaaca ccttaaaatt aaatttggaa aatgaaaaaa 1080  
agagaatggt atccgatgct tttatgaaaa aacaagaagg aatcattgta aactatatag 1140  
tgacttgca taaggattct gctattggca ttagtaaaaa ggcaattgat atattattga 1200  
taatcaatga aaatacattt cctgaatggc caaatgtaga tagatggctt tctattttgc 1260  
caaaatattt tacggattct ttttcaaaat caaaaatatt gcatagtga gattggctat 1320  
ttgaagagtg gttatactgg tttgaacctg aaaaatagatt ttggttttta ggagaattag 1380  
atcctgttga taatgagcat ttgaaaaata gcatagttgt acaagaacac ccttttccag 1440  
tagaatcatt agaagttcta cttatgaagc taggaacaag cgaattacat gaaattggta 1500  
tggaatgagg ttaaatgtac ttttaacgga tatatctttt acaatagagc tgaattttgt 1560  
tagagtttaa aatgaaaaaa caactaagtt ataacgaaag gagctaacac ttgatggaaa 1620  
attacgtgtc aatagtaaaa atcgaaaaca atctttccgt gtgcttttac aacagctcgg 1680  
agaaagtagt agcaattgct aagaaaatga atgagattaa cgaagaagct tatatgcatg 1740

```

gttacaaattg ggaagcattt ttcaactact atttacctaa atatgctcca gatgtccttag 1800
aaggaatggg ctcgatccg gaagcgggaa tgtatgtggc gtattacacg ctatcacctg 1860
aaactgaggc acgagcagaa aaacttggtc aagtaattac gaatctcatc gaaaatgaag 1920
aactacttta tcaataaatt gaaaatgaag gcaataatat tagttgggat aattaatcct 1980
ttttctaaaa aatccttatt tatttattcg tatagtatta gcaagagggtg aagaacctgt 2040
ataatataat tgacgatatt ttaaagcatt agatcctatt ggcagatgct cttaaaacgt 2100
taaacagtaa aataaaaaat ctctaaaaca tttgaaaccc tttgtaatta aaagggtgaat 2160
gttttagaga tttttttatc ttgcatctcc catttttatt ccgttggttt tgtggcaaat 2220
tttattaaaa ctagtccaag taattacgaa tctcattgaa aacgaagaac tactttataa 2280
aatagcaaaa aattaggaca agcagattat tgagatgatt gatcctttac tttaataata 2340
atthttatgt aaactcatcc cttattaggt gttctattgt atgacttgag agtagtthtt 2400
ttgagaattt caagcaataa atttaaatat attagagagt ctaaaattag cactaatccc 2460
taaaaaagata tgaacgatat gtgaacgatg ataccaagaa atgaaaaaat ttctatacta 2520
tattcaaat gtaagcttgg gactgctata attagtactt attgaggcga tataatgcc 2580
catacattaa atacagaata aactcattct ttaagataat aattacatct aaggagacta 2640
atcatgaaaa gaaagataag ttctatcatt gtagtcggga taatgttctt tcaatcatta 2700
ac 2702

```

&lt;210&gt; 27

&lt;211&gt; 643

&lt;212&gt; DNA

<213> *Listeria monocytogenes*

&lt;400&gt; 27

```

agcatttctt taccaagagg ggcgatccgt atcaaaacat acggctctta tcaattcaca 60
ccagaaggca tccaagttcg attcatggac cgagatgaca acgaactatc agacctaac 120
caaaccttcc cataacgaa taacgaagca taactaggtc aaaagacacc cgaaaaagaa 180
aaaatgcaat aacttaaaga aaaccattga caaacaagcg atttaaacat aaaatggtat 240
ttggctgttg aaaagacagt gccatttgc ctgatagctc agctggatag agcaacggcc 300
ttctaagccg tcggctgggg gttcgaatcc ctctcaggac gtaatatgaa gcgccgtaaa 360
cgttgttaat acaatgttta cggcgctttt tggtttttcg aagttcaaat aaagtacaaa 420
aaatttaaat tccattaatc tttttcatta atttatatga attaggcttc taaagtcatt 480
actatagtgt tttggcccaa tcttaatttt gaagaatata atctttaatt ttggtattag 540
tcttatttag tagcatttgc tccataaaaa caatagaaaa attaatacca gtcttatata 600
aaaatcttct catgacgaga agatttttat tttgcgattg agc 643

```

&lt;210&gt; 28

&lt;211&gt; 6123

&lt;212&gt; DNA

&lt;213&gt; Shuttle integration vector pPL2

&lt;400&gt; 28

```

gacgtcaata cgactcacta tagggcgaat tgggtaccgg gccccccctc gaggtcgacg 60
gtatcgataa gcttgatata gaattcctgc agcccggggg atccactagt tctagagcgg 120
ccgccaccgc ggtggagctc cagcttttgt tccctttagt gagggttaat gacgtcgcta 180
tttaacgacc ctgccctgaa ccgacgaccg ggtcgaattt gctttcgaat ttctgccatt 240
catccgctta ttatcactta ttcaggcgta gcaccaggcg tttaagggca ccaataactg 300
ccttaaaaaa attacgcccc gccctgccac tcatcgagat actgttgtaa ttcattaagc 360
attctgccga catggaagcc atcacagacg gcatgatgaa cctgaatcgc cagcggcatc 420
agcaccttgt cgccttgctg ataataattg cccatgggtg aaacgggggg gaagaagttg 480
tccatattgg ccacgtttta atcaaaactg gtgaaactca cccagggtat ggctgagacg 540
aaaaacatat tctcaataaa ccttttaggg aaataggcca ggttttcacc gtaacacgcc 600
acatcttgcg aatatatgtg tagaaactgc cggaaatcgt cgtggtattc actccagagc 660
gatgaaaacg tttcagtttg ctcatggaaa acggtgtaac aagggtgaac actatcccat 720
atcacagct caccgtcttt cattgccata cgggaattccg gatgagcatt catcaggcgg 780
gcaagaatgt gaataaaggc cggataaaac ttgtgcttat tttctttac ggtctttaaa 840
aaggccgtaa tatccagctg aacggctctg ttatagggtac attgagcaac tgactgaaat 900
gcctcaaaaat gttctttacg atgccattgg gatatatcaa cgggtgtata tccagtgtat 960
ttttctcca ttttagcttc cttagctcct gaaaatctcg ataactcaaa aaatacgccc 1020
ggtagtgatc ttatttcatt atggtgaaag ttggaacctc ttactgtccg atcaacgtct 1080
cattttcgcc aaaagttggc ccagggtctc cgggtatcaa caggagacacc aggttttatt 1140
tattctcgca agtgatcttc cgtcacaggt atttattcgg cgcaaagtgc gtcgggtgat 1200

```

gctgccaaact tactgattta gtgtatgat gtgtttttga ggtgctccag tggcttctgt 1260  
ttctatcagc tgtccctcct gttcagctac tgacggggtg gtgcgtaacg gcaaaagcac 1320  
cgccggacat cagcgctagc ggagtgtata ctggcttact atgttggcac tgatgagggt 1380  
gtcagtgaag tgcttcatgt ggcaggagaa aaaagctgc accggtgcgt cagcagaata 1440  
tgtgatacag gatataattcc gcttccctgc tcaactgactc gctacgctcg gtcgttcgac 1500  
tgccggcgagc ggaagtggct tacgaacggg gcggagattt cctggaagat gccaggaaga 1560  
tacttaacag ggaagtgaga gggccgcgcc aaagccgttt tcccataggc tccgcccccc 1620  
tgacaagcat cacgaaatct gacgctcaaa tcagtgggtg cgaaacccga caggactata 1680  
aagataccag gcgtttcccc ctggcggtc cctcgtgcgc tctcctgttc ctgcctttcg 1740  
gtttaccggt gtcattccgc tgttatggcc gcgtttgtct cattccacgc ctgacactca 1800  
gttcggggtg ggcagttcgc tccaagctgg actgtatgca cgaaccccc gttcagtcg 1860  
accgctgcgc cttatccggt aactatcgtg ttgagtccaa ccggaaaaga catgcaaaag 1920  
caccactggc agcagccact ggtaattgat ttagaggagt tagtcttgaa gtcatgcgcc 1980  
ggtaaggct aaactgaaag gacaagtttt ggtgactgcg ctctccaag ccagttacct 2040  
cggttcaaaag agttggtagc tcagagaacc ttcgaaaaac cgccctgcaa ggcggttttt 2100  
tcgttttcag agcaagagat tacgcgagc ccaaaacgat ctcaagaaga tcattctatt 2160  
aatcagataa aatatttcta gatcttcagt caatttatct cttcaaagt agcacctgaa 2220  
gtcagcccca tacgatataa gttgtaattc tccgcccgtt gccctcatct gttacgccgg 2280  
cggtagccgg ccagcctcgc agagcaggat tcccgttgag caccgccagg tgcgaataag 2340  
ggacagtga gaaggaaac ccgctcgcgg gtgggcctac ttcacctatc ctgcccggt 2400  
gacgcggtg gatacaccaa ggaagtccta cacgaacct ttggcaaaat cctgtatatc 2460  
gtgcgaaaaa ggatggatat tccgaaaaaa tccgtataat gaccccgaag cagggttatg 2520  
cagcggaaaa gcgctgcttc cctgctgttt tgtggaatat ctaccgactg gaaacaggca 2580  
aatgcaggaa attactgaac tgaggggaca ggcgagaggc atgcgtggag ggaaagaaga 2640  
acgctgttga aaaaatcttc tctggactac ttgaaacaaa agaattaaag tcattttata 2700  
aaaaccttga gaaaaacat cttgatataa aaactattta taacgaatat ttatttcaat 2760  
gtaataataa ataatttta ttattacata aaatgtttgt ggtattattt gtggtatata 2820  
tatcctaaat ggctttatat cagtgtgtgt taatccctct caggacgtta aatagtaatg 2880  
taaagaaatc tctaaaacgt tgaaaagcct tgatattaaa gggcggtatg atgttttggg 2940  
gtttttttta tatcgtataa taccggtttt attccgttgt ttttgtggca tttgtggtaa 3000  
aatttgttgt attttcatct gtttttagtg tgaaaaagc atctactttg gactgattat 3060  
gttgtcttaa attagagctt agatgactat agtattttta tgttgtatta atgtcatcat 3120  
gaccaagcct atcagctaca taaataatat ccataccgc ttctacacat aagcctgtat 3180  
gcgtatgtcg tagcttgtgt aatgtcactg gttcagaatt gattgtacta catatcttct 3240  
tcaaagcttt attacaagac gcgttgtcta ctggcttatt gtggtaaagt atgaataata 3300  
acatcaatgg attcctaata gcatgttcct tcataataatc agtatgcaa tttaaatacg 3360  
aatgtaataa ttgagcggta gagttatcaa tatagatcac tcgtgatttt tttgttttgg 3420  
tatcctaaat tgtattagtg tacttgtaat cccaagcttt attcacagtt attgaacgtt 3480  
tagtgaaatt aatatccttc tttgttagtg caataatttc ttcgaacctc atgcctgtct 3540  
ggacagctag aaagataact gctcgtgata tagaatgaaa ttttgcaagt tcttctaata 3600  
gtaaatgaac tttgtctgtt tcataaaatt gtgctttatt tttcgctacg tccgtccgc 3660  
ttatatgagc ccctatagtg gggtttttct tcatgtaacc taaatgaaca gccttgtaa 3720  
aaaatcgctc aattttgcgg tgtctggtg ctacagtggg tattgcatag tctacagata 3780  
aatgattaat aaattgttga tattgaaccg catcaatcga attaagtta attttttcat 3840  
cgaaataatc aacgaattga ttataagcaa gatcgtataa attaatagta gattgactac 3900  
ttttcccatc tttaaatggt ttcataaata gcgtataaaa ttctttgaag ttccattctt 3960  
tcagagaact actatcatgc tgaacttggt ttaataattt agatgcttta tacattaagt 4020  
ttgtttcact tgtatctgtc aaacgctttt ctttccattc accatcgact tttatagcta 4080  
ggcgaacaca atatttaccg tttgttaatt tttttatctt catataacc accactgtt 4140  
tatttttggg gatctttttt tcagaaaatc ccagtacgta attaatgatt tgagaattaa 4200  
ttttatattg attaatacta agtttaccga gttttcacct aaaaaacaaa tgatgagata 4260  
ataactccaa aggctaaaga ggactatacc aactatttgt aataattctg taacagttga 4320  
aaagcgaacg tgtattctta gggcttgaga tgtactgctg ggtaaaccct tatagtgtaa 4380  
gtgggatgtg aacgttaatc aacaactttc cgtatgggaa acctattgtt ttttgttaat 4440  
agaaaaactt aatacatattg taatataaaa accggcagtt tttccgttct tcgtgactcg 4500  
aaatgaattg ccagatgagt ttatggtatt ctataataga aggtatggag gatgttatat 4560  
aatgagacag aattatgatg atcgaaagct agcttggcac tggccgtcgt tttacaacgt 4620  
cgtgactggg aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca tccccctttc 4680  
gccagctggc gtaatagcga agaggccgc accgatcgcc cttccaaca gttgcgcagc 4740  
ctgaattggc aatggcgctt gatgcggtat tttctcctta cgcattctgt cggtatttca 4800  
caccgcataa caaatgggtc ggatctggag ctgtaatata aaaaccttct tcaactaacg 4860  
gggcaggtta gtgacattag aaaaccgact gtaaaaagta cagtcggcat tatctcatat 4920

tataaaagcc agtcattagg cctatctgac aattcctgaa tagagtccat aaacaatcct 4980  
gcatgataac catcacaaac agaatgatgt acctgtaaag atagcggtaa atatattgaa 5040  
ttacctttat taatgaattt tcctgctgta ataatgggta gaaggtaatt actattatta 5100  
ttgatattta agttaaaccc agtaaatgaa gtccatggaa taatagaaag agaaaaagca 5160  
ttttcaggta taggtgtttt gggaaacaat tccccgaac cattatattt ctctacatca 5220  
gaaaggata aatcataaaa ctctttgaag tcattcttta caggagtcca aataccagag 5280  
aatgttttag atacaccatc aaaaattgta taaagtggct ctaacttacc ccaataacct 5340  
aactctccgt cgctattgta accagttcta aaagctgtat ttgagtttat cacccttgtc 5400  
actaagaaaa taaatgcagg gtaaaattta tatccttctt gttttatggt tcggtataaa 5460  
acactaatat caatttctgt ggttatacta aaagtcgttt gttggttcaa ataagtatta 5520  
aatatctctt ttctcttcca attgtctaaa tcaattttat taaagtccat ttgatatgcc 5580  
tcctaaattt ttatctaaag tgaatttagg aggccttactt gtctgctttc ttcattagaa 5640  
tcaatccttt tttaaaagtc aatattactg taacataaat atatatttta aaaatatccc 5700  
actttatcca attttcgttt gttgaactaa tgggtgcttt agttgaagaa taaagaccac 5760  
attaaaaaat gtggtccttt gtgttttttt aaaggatttg agcgtagcga aaaatccttt 5820  
tctttcttat cttgataata agggtaacta ttgccagat ccgaaccatt tgatatggtg 5880  
cactctcagt acaatctgct ctgatgccgc atagttaagc cagccccgac acccgccaac 5940  
acccgctgac gcgcccgtgac gggcttgtct gctcccggca tccgcttaca gacaagctgt 6000  
gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag 6060  
acgaaagggc ctcgtgatac gcctattttt ataggttaat gtcataataa taatgggttc 6120  
tta 6123

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
**WO 2003/092600 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/00,  
15/09, 15/63, 15/70, 15/74

(74) Agent: FIELD, Bret E.; Bozicevic, Field & Francis, 200  
Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).

(21) International Application Number:  
PCT/US2003/013492

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 29 April 2003 (29.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/136,860 30 April 2002 (30.04.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE  
REGENTS OF THE UNIVERSITY OF CALIFORNIA  
[US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA  
94607-5200 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): PORTNOY, Daniel  
A. [US/US]; 1196 Curtis Street, Albany, CA 94706 (US).  
CALENDAR, Richard [US/US]; 940 Euclid Avenue,  
Berkeley, CA 94708 (US). LAUER, Peter M. [US/US];  
5719 Oak Grove Avenue, Oakland, CA 94618 (US).

(88) Date of publication of the International search report:  
8 April 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2003/092600 A3

(54) Title: SITE SPECIFIC LISTERIA INTEGRATION VECTORS AND METHODS FOR USING THE SAME

(57) Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/13492

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																										
IPC(7) : C12N 15/00, 15/09, 15/63, 15/70, 15/74																										
US CL : 435/320.1																										
According to International Patent Classification (IPC) or to both national classification and IPC																										
<b>B. FIELDS SEARCHED</b>																										
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/320.1																										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																										
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet																										
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																										
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
X,P	LAUER et al. Construction, Characterization, and Use of Two Listeria monocytogenes Site-Specific Phage Integration Vectors. Journal of Bacteriology. August 2002. Volume 184, Number 15, pages 4177-4186, see entire document.	1-11																								
X	SCHAFERKORDT, S. et al. Vector Plasmid for Insertional Mutagenesis and Directional Cloning in Listeria spp. BioTechniques. 1995, Volume 19, Number 5, pages 720-725, see entire document.	1-9																								
X	FORTINEAU et al. Optimization of green fluorescent protein expression vectors for in vitro and in vivo detection of Listeria monocytogenes. Res. Microbiol. 2000, Volume 151, pages 353-360, see entire document.	1-9																								
Y	REITER et al. Transfer RNA genes frequently serve as integration sites for prokaryotic genetic elements. Nucleic Acids Research. 1989, Volume 17, Number 5, pages 1907-1914, see entire document.	5																								
A	SCOTT et al. Conjugative Transposition. Annu. Rev. Microbiol. 1995, Volume 49, pages 367-397, see entire document.	1-11																								
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E</td> <td>earlier application or patent published on or after the international filing date</td> <td>*Y</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*&amp;</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E	earlier application or patent published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&	document member of the same patent family	*O	document referring to an oral disclosure, use, exhibition or other means			*P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
*E	earlier application or patent published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&	document member of the same patent family																							
*O	document referring to an oral disclosure, use, exhibition or other means																									
*P	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search 12 November 2003 (12.11.2003)		Date of mailing of the international search report 23 DEC 2003																								
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer Patricia A. Duffy Telephone No. 703-308-0196																								

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/13492

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 20, 21, 22, 24  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-11

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claims 1-11, drawn to an integration vector capable of site-specific *Listeria* genome integration.

Group 2, claim 12, drawn to a method of transforming cells using the integration vector.

Group 3, claims 13, 16-19, drawn to a *Listeria* transformed with the integration vector and cultures and compositions thereof.

Group 4, claims 14-15, drawn to a method of eliciting or boosting a cellular immune response using the *Listeria* transformed with the integration vector.

The inventions listed as Groups 1-7 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group 1 is an integration vector capable of site-specific *Listeria* genome integration. This technical feature is anticipated by the art according to Schaeferkordt et al (BioTechniques, 19(5):720-725, 1995) that teaches an insertion site-specific vector plasmid for cloning in *Listeria* species. Inasmuch as, the technical feature of Group 1 does not define a contribution over the art, the technical feature of Group 1 is not "special" within the meaning of PCT Rule 13.2 and therefore Groups 1-7 lack unity of invention.

**Continuation of B. FIELDS SEARCHED Item 3:**

WEST, MEDLINE, EMBASE, DERWENT.

SEARCH TERMS: VECTOR, LISTERIA, INTEGRATE, PHAGE, LISTERIOPHAGE, INTEGRASE, ATT, tRNA, SITE-SPECIFIC, SPECIFIC INTEGRATION.